MA31040B1 - Anticorps anti-cd20 avec une augmentation de l'affinite de fixation sur le recepteur fc et de la fonction effectrice. - Google Patents

Anticorps anti-cd20 avec une augmentation de l'affinite de fixation sur le recepteur fc et de la fonction effectrice.

Info

Publication number
MA31040B1
MA31040B1 MA29059A MA29059A MA31040B1 MA 31040 B1 MA31040 B1 MA 31040B1 MA 29059 A MA29059 A MA 29059A MA 29059 A MA29059 A MA 29059A MA 31040 B1 MA31040 B1 MA 31040B1
Authority
MA
Morocco
Prior art keywords
antibodies
invention concerns
receptor
molecules
abms
Prior art date
Application number
MA29059A
Other languages
English (en)
French (fr)
Inventor
Pablo Umana
Peter Brunker
Claudia Ferrara
Tobias Suter
Ursula Puntener
Ekkehard Mossner
Original Assignee
Glycart Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34572912&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31040(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glycart Biotechnology Ag filed Critical Glycart Biotechnology Ag
Publication of MA31040B1 publication Critical patent/MA31040B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01144—Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase (2.4.1.144)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
MA29059A 2003-11-05 2006-05-24 Anticorps anti-cd20 avec une augmentation de l'affinite de fixation sur le recepteur fc et de la fonction effectrice. MA31040B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51709603P 2003-11-05 2003-11-05

Publications (1)

Publication Number Publication Date
MA31040B1 true MA31040B1 (fr) 2010-01-04

Family

ID=34572912

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29059A MA31040B1 (fr) 2003-11-05 2006-05-24 Anticorps anti-cd20 avec une augmentation de l'affinite de fixation sur le recepteur fc et de la fonction effectrice.

Country Status (40)

Country Link
US (8) US9296820B2 (enExample)
EP (5) EP1692182B1 (enExample)
JP (5) JP4653109B2 (enExample)
KR (3) KR101364858B1 (enExample)
CN (4) CN104829719A (enExample)
AT (1) ATE463513T1 (enExample)
AU (1) AU2004287643C1 (enExample)
BE (1) BE2016C008I2 (enExample)
BR (2) BR122020013239B1 (enExample)
CA (1) CA2544865C (enExample)
CR (1) CR11848A (enExample)
CY (6) CY1110301T1 (enExample)
DE (1) DE602004026470D1 (enExample)
DK (5) DK1692182T3 (enExample)
EA (4) EA202091901A1 (enExample)
EC (2) ECSP066603A (enExample)
ES (5) ES2672640T3 (enExample)
FR (1) FR15C0076I2 (enExample)
HK (1) HK1213574A1 (enExample)
HR (5) HRP20100303T1 (enExample)
HU (5) HUE042914T2 (enExample)
IL (4) IL175367A (enExample)
LT (4) LT2380911T (enExample)
LU (2) LU92632I2 (enExample)
MA (1) MA31040B1 (enExample)
ME (3) ME02332B (enExample)
MX (2) MXPA06004836A (enExample)
NL (1) NL300801I2 (enExample)
NO (6) NO347530B1 (enExample)
NZ (2) NZ588860A (enExample)
PL (5) PL2380911T3 (enExample)
PT (5) PT2380911T (enExample)
RS (5) RS54450B1 (enExample)
SG (3) SG10202008722QA (enExample)
SI (5) SI2380911T1 (enExample)
TN (1) TNSN06126A1 (enExample)
TR (2) TR201809892T4 (enExample)
UA (1) UA91823C2 (enExample)
WO (1) WO2005044859A2 (enExample)
ZA (1) ZA200604547B (enExample)

Families Citing this family (888)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CA2897608C (en) 2003-05-09 2018-07-31 Duke University Cd20-specific antibodies and methods employing same
NO347530B1 (no) * 2003-11-05 2023-12-11 Roche Glycart Ag Et humanisert type II anti-CD20 antistoff og vertscelle som produserer et humanisert type II anti-CD20 antistoff samt en fremgangsmåte for fremstilling og en farmasøytisk sammensetning.
EP1781378A2 (en) * 2004-07-22 2007-05-09 Genentech, Inc. Method of treating sjögren's syndrome
CA2573192C (en) 2004-08-04 2013-09-10 Applied Molecular Evolution Inc. Variant fc regions
ZA200702335B (en) 2004-10-05 2009-05-27 Genentech Inc Method for treating vasculitis
JP5336089B2 (ja) 2005-02-07 2013-11-06 ロシュ グリクアート アクチェンゲゼルシャフト Ｅｇｆｒを結合する抗原結合分子、それをコードするベクターおよびその使用
BRPI0611445A2 (pt) * 2005-05-09 2010-09-08 Glycart Biotechnology Ag molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica
US7601335B2 (en) 2005-05-20 2009-10-13 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
KR20080032065A (ko) * 2005-06-03 2008-04-14 제넨테크, 인크. 푸코실화 수준이 조절된 항체의 생성 방법
WO2007009469A2 (en) 2005-07-21 2007-01-25 Genmab A/S Potency assays for antibody drug substance binding to an fc receptor
CN101291954B (zh) * 2005-08-26 2013-03-27 罗氏格黎卡特股份公司 具有改变的细胞信号传导活性的修饰的抗原结合分子
AU2012216702B2 (en) * 2005-08-26 2014-12-04 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP1957099B1 (en) * 2005-11-07 2015-03-25 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2631961A1 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling relating to antibodies that bind to il-22
RU2450020C2 (ru) 2006-01-05 2012-05-10 Дженентек, Инк. АНТИТЕЛА ПРОТИВ EphB4 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2623610B1 (en) * 2006-02-10 2015-04-29 Life Technologies Corporation Labeling and detection of post translationally modified proteins
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
EP3456351A1 (en) * 2006-04-05 2019-03-20 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
PT2032606E (pt) 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
BRPI0710411A2 (pt) * 2006-06-06 2012-04-10 Genentch Inc Empresa Americana Métodos para tratar um tumor, para tratar uma condição patológica associada à angiogênese, para estimular a proliferação celular endotelial, para reduzir ou inibir a diferenciação celular endotelial, para reduzir ou inibir o desenvolvimento arterial, para reduzir ou inibir a perfusão vascular tumoral para aumentar a eficácia de um agente anti-angiogênico, usos de um antagonista de dll4 e uso de um agonisra de dll4
AR062223A1 (es) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
EP2084188A2 (en) * 2006-10-12 2009-08-05 Genentech, Inc. Antibodies to lymphotoxin-alpha
EP2845866B1 (en) 2006-10-27 2017-05-03 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
AU2013202392B2 (en) * 2006-12-20 2016-02-25 Mmrglobal, Inc. Antibodies and methods for making and using them
CN103709249B (zh) * 2006-12-20 2016-02-24 Mmr全球公司 抗体及其制备和使用方法
ES2426158T3 (es) 2007-01-22 2013-10-21 Genentech, Inc. Precipitación con polielectrolito y purificación de anticuerpos
EP2125013A4 (en) * 2007-01-26 2010-04-07 Bioinvent Int Ab DLL4 SIGNALING INHIBITOR AND ITS USES
CA2676766A1 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
HUE026728T2 (en) 2007-05-14 2016-06-28 Medimmune Llc A method for reducing eosinophil levels
MX2009013328A (es) 2007-06-25 2010-06-02 Esbatech An Alcon Biomedical R Metodos para modificar anticuerpos, y anticuerpos modificados con propiedades funcionales mejoradas.
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
PL2176296T3 (pl) 2007-07-16 2012-07-31 Genentech Inc Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
CA2697482C (en) * 2007-09-05 2016-05-31 F. Hoffmann-La Roche Ag Combination therapy with type i and type ii anti-cd20 antibodies
RU2526512C2 (ru) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Модифицированная константная область антитела
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
MX373155B (es) 2007-11-07 2020-04-21 Genentech Inc Composiciones y metodos para el tratamiento de trastornos microbianos.
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CN101945667A (zh) * 2007-12-21 2011-01-12 健泰科生物技术公司 利妥昔单抗不应性类风湿性关节炎患者的疗法
EP2234600B1 (en) * 2007-12-21 2014-08-20 F. Hoffmann-La Roche AG Antibody formulation
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
CN101983071A (zh) * 2008-03-25 2011-03-02 罗氏格黎卡特股份公司 具有增加的抗体依赖性细胞毒性(adcc)的ⅱ型抗cd20抗体与环磷酰胺、长春新碱和多柔比星联合治疗非霍奇金淋巴瘤的应用
CN112481367A (zh) * 2008-03-31 2021-03-12 健泰科生物技术公司 用于治疗和诊断哮喘的组合物和方法
EP2279410B1 (en) * 2008-04-22 2015-11-11 The Rockefeller University Methods of identifying anti-inflammatory compounds
US20090269339A1 (en) * 2008-04-29 2009-10-29 Genentech, Inc. Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
KR101054362B1 (ko) * 2008-07-03 2011-08-05 재단법인 목암생명공학연구소 재조합 단백질의 푸코스 함량을 감소시키는 방법
DK2318832T3 (da) 2008-07-15 2014-01-20 Academia Sinica Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
AU2009303526B2 (en) 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
MX2011006870A (es) 2008-12-23 2011-07-19 Genentech Inc Variantes de inmunoglobulina con union alterada a proteina a.
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
CA2753988C (en) 2009-03-25 2017-04-25 Genentech, Inc. Novel anti-.alpha.5.beta. integrin antibodies and uses thereof
US8410250B2 (en) 2009-03-25 2013-04-02 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
AU2010230563A1 (en) 2009-04-02 2011-09-22 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain Fab fragments
EP2417164A1 (en) 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-2/anti-c-met antibodies
PE20120550A1 (es) 2009-04-07 2012-05-21 Roche Glycart Ag ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET
US20100256340A1 (en) 2009-04-07 2010-10-07 Ulrich Brinkmann Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
JP5921433B2 (ja) 2009-07-24 2016-05-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 攪拌システム
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
CN102498129B (zh) 2009-07-31 2016-03-02 霍夫曼-拉罗奇有限公司 使用bv8拮抗剂或g-csf拮抗剂抑制肿瘤转移
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CA2769595A1 (en) 2009-08-14 2011-02-17 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
CN102666874B (zh) * 2009-10-07 2016-06-01 宏观基因有限公司 由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法
AU2010310585A1 (en) 2009-10-22 2012-05-03 Genentech, Inc. Anti-hepsin antibodies and methods using same
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
SMT201700248T1 (it) 2009-11-02 2017-07-18 Univ Washington Composizioni terapeutiche di nucleasi e metodi
AU2010315101B2 (en) 2009-11-04 2016-01-28 Fabrus Llc Methods for affinity maturation-based antibody optimization
WO2011057120A1 (en) 2009-11-05 2011-05-12 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
ES2565208T3 (es) 2009-12-11 2016-04-01 F. Hoffmann-La Roche Ag Anticuerpos anti-VEGF-C y métodos de uso de los mismos
MA33892B1 (fr) 2009-12-22 2013-01-02 Roche Glycart Ag Anticorps anti-her3, et leurs utilisations
DK2516465T3 (en) 2009-12-23 2016-06-06 Hoffmann La Roche ANTI-BV8 ANTIBODIES AND APPLICATIONS THEREOF
RU2573994C2 (ru) * 2010-02-10 2016-01-27 Иммьюноджен, Инк Антитела против cd20 и их применение
MX336473B (es) 2010-02-11 2016-01-20 Hoffmann La Roche Ensayo mediante adcc nk facs tridimensional.
MX2012008958A (es) 2010-02-18 2012-08-23 Genentech Inc Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
JP6093692B2 (ja) 2010-03-24 2017-03-08 ジェネンテック， インコーポレイテッド 抗ｌｒｐ６抗体
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
EP2374816B1 (en) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
WO2011124635A1 (en) 2010-04-07 2011-10-13 Humalys Binding molecules against chikungunya virus and uses thereof
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
MX342590B (es) * 2010-04-27 2016-10-05 Roche Glycart Ag Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
EP2975409B1 (en) 2010-05-10 2018-10-31 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
SG185430A1 (en) 2010-06-03 2012-12-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
TW201204388A (en) 2010-06-18 2012-02-01 Genentech Inc Anti-Axl antibodies and methods of use
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
JP2013539962A (ja) 2010-07-09 2013-10-31 ジェネンテック， インコーポレイテッド 抗ニューロピリン抗体及び使用方法
EP2591099B1 (en) 2010-07-09 2020-11-18 Bioverativ Therapeutics Inc. Chimeric clotting factors
EP2409989A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Method to improve glycosylation profile for antibody
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
FR2962908A1 (fr) 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
EP2600895A1 (en) 2010-08-03 2013-06-12 Hoffmann-La Roche AG Chronic lymphocytic leukemia (cll) biomarkers
CA2805564A1 (en) 2010-08-05 2012-02-09 Stefan Jenewein Anti-mhc antibody anti-viral cytokine fusion protein
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
BR112013003361B8 (pt) 2010-08-13 2022-01-25 Roche Glycart Ag Anticorpo, composição, conjugado de anticorpo,formulação farmacêutica e uso do anticorpo
MX2013001336A (es) 2010-08-13 2013-03-08 Roche Glycart Ag Anticuerpos ani-tenascina c a2 y metodos de utilizacion.
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
AR082693A1 (es) 2010-08-17 2012-12-26 Roche Glycart Ag Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
JP5758004B2 (ja) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
KR101603001B1 (ko) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
US20120089541A1 (en) 2010-08-31 2012-04-12 Genentech, Inc. Biomarkers and methods of treatment
PL3590949T3 (pl) 2010-10-01 2022-08-29 Modernatx, Inc. Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania
CA2813738A1 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
EP2638067A2 (en) 2010-11-08 2013-09-18 Genentech, Inc. Subcutaneously administered anti-il-6 receptor antibody
CN103228674B (zh) 2010-11-10 2019-07-05 霍夫曼-拉罗奇有限公司 用于神经疾病免疫疗法的方法和组合物
SG190726A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
EP2646470B1 (en) 2010-11-30 2017-03-01 F. Hoffmann-La Roche AG Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier
JP2014507384A (ja) 2010-12-16 2014-03-27 ロシュ グリクアート アーゲー Ｍｄｍ２阻害剤とのアフコシル化ｃｄ２０抗体の併用療法
EP2652498B1 (en) 2010-12-16 2018-04-18 F.Hoffmann-La Roche Ag Diagnosis and treatments relating to th2 inhibition
UA113838C2 (xx) 2010-12-20 2017-03-27 Антитіло, яке зв'язує мезотелін, та імунокон'югат
MX2013007168A (es) 2010-12-22 2013-11-04 Genentech Inc Anticuerpo anti-pcsk9 y metodos de uso.
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CA2824252A1 (en) * 2011-02-10 2012-08-16 Roche Glycart Ag Improved immunotherapy
RU2013141078A (ru) 2011-02-28 2015-04-10 Ф. Хоффманн-Ля Рош Аг Одновалентные антигенсвязывающие белки
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
KR20140021589A (ko) 2011-04-07 2014-02-20 제넨테크, 인크. 항-fgfr4 항체 및 사용 방법
KR102161657B1 (ko) 2011-04-29 2020-10-06 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료적 뉴클레아제 조성물 및 방법
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
EP2710035B1 (en) 2011-05-16 2017-04-12 F. Hoffmann-La Roche AG Fgfr1 agonists and methods of use
WO2012171996A1 (en) 2011-06-15 2012-12-20 F. Hoffmann-La Roche Ag Anti-human epo receptor antibodies and methods of use
FR2976811A1 (fr) 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
CN110229235A (zh) 2011-06-22 2019-09-13 霍夫曼-拉罗奇有限公司 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞
TW201306866A (zh) 2011-06-30 2013-02-16 Genentech Inc 抗－ｃ－ｍｅｔ抗體調配物
CA2842375A1 (en) 2011-08-17 2013-02-21 Erica Jackson Neuregulin antibodies and uses thereof
BR112014003599A2 (pt) 2011-08-17 2018-04-17 Genentech Inc método de inibição da angiogênese tumoral, método de supressão do crescimento tumoral e método de tratamento de tumor
WO2013026832A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Anti-mcsp antibodies
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2846083A1 (en) 2011-09-15 2013-03-21 Genentech, Inc. Methods of promoting differentiation
BR112014006419A2 (pt) 2011-09-19 2018-08-07 Genentech Inc métodos para tratar um paciente com câncer, kit e artigo
MX2014002996A (es) 2011-09-23 2014-05-28 Roche Glycart Ag Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
KR102276528B1 (ko) * 2011-09-30 2021-07-12 추가이 세이야쿠 가부시키가이샤 이온 농도 의존성 결합 분자 라이브러리
AU2012315474B2 (en) 2011-09-30 2017-10-26 Teva Pharmaceuticals Australia Pty Ltd. Antibodies against TL1a and uses thereof
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
SG11201401287SA (en) 2011-10-05 2014-05-29 Genentech Inc Methods of treating liver conditions using notch2 antagonists
CA2850032C (en) 2011-10-14 2022-06-07 Genentech, Inc. Anti-htra1 antibodies and methods of use
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
EA201490879A1 (ru) 2011-10-28 2014-08-29 Дженентек, Инк. Терапевтические комбинации и способы лечения меланомы
JP2015504413A (ja) 2011-10-28 2015-02-12 パトリス リミテッド Ｐａｔ−ｌｍ１エピトープおよびそれを使用するための方法
US9580509B2 (en) 2011-11-07 2017-02-28 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
BR112014012005A2 (pt) 2011-11-21 2017-12-19 Genentech Inc composições, métodos, formulação farmacêutica e artigo
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
PT2791160T (pt) 2011-12-16 2022-07-04 Modernatx Inc Composições arnm modificado
CN104011221B (zh) 2011-12-20 2019-01-08 米迪缪尼有限公司 用于双特异性抗体支架的经修饰的多肽
RU2625033C2 (ru) 2011-12-22 2017-07-11 Ф. Хоффманн-Ля Рош Аг Система индикации на основе полноразмерного антитела для эукариотических клеток и ее применение
SG10201805622QA (en) 2011-12-22 2018-08-30 Hoffmann La Roche Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
SG11201403443WA (en) 2011-12-22 2014-07-30 Hoffmann La Roche Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
CN104066449B (zh) 2012-01-18 2018-04-27 霍夫曼-拉罗奇有限公司 抗lrp5抗体及使用方法
KR20140119114A (ko) 2012-01-18 2014-10-08 제넨테크, 인크. Fgf19 조절제의 사용 방법
JP6486686B2 (ja) 2012-02-10 2019-03-20 ジェネンテック， インコーポレイテッド 単鎖抗体及び他のヘテロ多量体
US20130209473A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
RU2624128C2 (ru) 2012-02-15 2017-06-30 Ф. Хоффманн-Ля Рош Аг Аффинная хроматография с применением fc-рецепторов
CA2865082A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
AU2013243955B2 (en) 2012-04-02 2018-02-22 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
AR090903A1 (es) 2012-05-01 2014-12-17 Genentech Inc Anticuerpos e inmunoconjugados anti-pmel17
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
KR102326359B1 (ko) 2012-05-18 2021-11-12 제넨테크, 인크. 고농도 모노클로날 항체 제제
US20150353639A1 (en) 2012-05-21 2015-12-10 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
MX2014014086A (es) 2012-05-23 2015-01-26 Genentech Inc Metodo de seleccion para agentes terapeuticos.
WO2013188855A1 (en) 2012-06-15 2013-12-19 Genentech, Inc. Anti-pcsk9 antibodies, formulations, dosing, and methods of use
TW201402611A (zh) 2012-06-21 2014-01-16 Univ Indiana Res & Tech Corp 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物
JP6309002B2 (ja) 2012-06-27 2018-04-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 標的に特異的に結合する少なくとも１つの結合実体を含む抗体Ｆｃ領域結合体を作製するための方法およびその使用
CN110256567B (zh) 2012-06-27 2023-04-25 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制靶向实体的方法及其用途
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
MX354303B (es) 2012-07-04 2018-02-23 Hoffmann La Roche Anticuerpos de anti-biotina y metodos de uso.
JP6148729B2 (ja) 2012-07-04 2017-06-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 共有結合している抗原−抗体結合体
CA2872184A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Anti-theophylline antibodies and methods of use
RU2670491C2 (ru) 2012-07-05 2018-10-23 Дженентек, Инк. Система экспрессии и секреции
JP6297550B2 (ja) 2012-07-09 2018-03-20 ジェネンテック， インコーポレイテッド 抗ｃｄ７９ｂ抗体を含む免疫複合体
HK1209043A1 (en) 2012-07-09 2016-03-24 基因泰克公司 Immunoconjugates comprising anti-cd22 antibodies
CA2873884A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
EA201590173A1 (ru) 2012-07-09 2015-09-30 Дженентек, Инк. Иммуноконъюгаты, содержащие антитела к cd22
NZ702201A (en) 2012-07-13 2018-01-26 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
CN104662045B (zh) * 2012-08-07 2019-04-05 罗切格利卡特公司 包含两种工程化改造成具有降低的和升高的效应器功能的抗体的组合物改进的免疫疗法
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
JP6211084B2 (ja) 2012-08-21 2017-10-11 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ ベンゾシクロオクチン化合物およびその使用
CN109053901A (zh) 2012-08-29 2018-12-21 霍夫曼-拉罗奇有限公司 血脑屏障穿梭体
CN104768581A (zh) 2012-09-07 2015-07-08 吉宁特有限公司 II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗
EP2905290B1 (en) 2012-10-05 2019-12-04 Kyowa Kirin Co., Ltd. Heterodimeric protein composition
KR20150064068A (ko) 2012-10-08 2015-06-10 로슈 글리카트 아게 2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법
EP2914629A1 (en) 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
EP2727943A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispecific antibodies against human EGFR, HER2 and HER3
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014071419A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
MX2015005757A (es) 2012-11-08 2015-11-18 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
AU2013345072B2 (en) 2012-11-13 2017-12-07 Genentech, Inc. Anti-hemagglutinin antibodies and methods of use
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
WO2014096672A1 (fr) 2012-12-17 2014-06-26 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
CA2889788A1 (en) 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
US20140194368A1 (en) * 2013-01-04 2014-07-10 Beech Tree Labs, Inc. Method of Treating Cancer by Administration of Low Levels of Heat Shock Protein 70 (HSP70)
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
RU2519546C1 (ru) * 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а
AU2014207342C1 (en) 2013-01-18 2019-04-04 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
EP2951208B1 (en) 2013-02-01 2019-11-13 Kira Biotech Pty Limited Anti-cd83 antibodies and use thereof
CN117843785A (zh) 2013-02-07 2024-04-09 Csl有限公司 Il-11r结合蛋白及其应用
AR094780A1 (es) 2013-02-13 2015-08-26 Laboratoire Français Du Fractionnement Et Des Biotechnologies ANTICUERPOS ANTI-TNF-a ALTAMENTE GALACTOSILADOS Y SUS USOS
CN104994879A (zh) 2013-02-22 2015-10-21 霍夫曼-拉罗奇有限公司 治疗癌症和预防药物抗性的方法
KR20180023035A (ko) 2013-02-26 2018-03-06 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
EP2961772A1 (en) 2013-02-26 2016-01-06 Roche Glycart AG Anti-mcsp antibodies
CA2896370A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
EP2968504B1 (en) * 2013-03-12 2019-12-18 University Of Utah Research Foundation Compositions and methods for inducing apoptosis
NZ751452A (en) 2013-03-13 2020-04-24 Genentech Inc Antibody formulations
KR20150127216A (ko) 2013-03-14 2015-11-16 제넨테크, 인크. 암의 치료 및 암 약물 내성의 예방 방법
KR20150127199A (ko) 2013-03-14 2015-11-16 제넨테크, 인크. 항-b7-h4 항체 및 면역접합체
SG11201507477XA (en) 2013-03-14 2015-10-29 Genentech Inc Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
MX2015011444A (es) 2013-03-15 2015-12-16 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
BR112015023140A8 (pt) 2013-03-15 2018-01-23 Genentech Inc proteínas de fusão, método para a fabricação da proteína de fusão, composições, ácido nucleico,vetor, célula hospedeira, métodos de produção de uma proteína de fusão, de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana, de tratamento da lesão renal, para acelerar ou melhorar a cicatrização, para a prevenção ou tratamento de uma condição cardiovascular, para tratamento da síndrome metabólica e para tratamento da endotoxemia.
CA2902910A1 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
BR112015021521A2 (pt) 2013-03-15 2017-10-10 Genentech Inc anticorpos anti-crth2 e métodos para seu uso
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
KR20150130451A (ko) 2013-03-15 2015-11-23 제넨테크, 인크. 암 치료 방법 및 항암제 내성 예방을 위한 방법
KR20220053691A (ko) 2013-03-15 2022-04-29 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
CN105164158A (zh) 2013-04-29 2015-12-16 豪夫迈·罗氏有限公司 消除对FcRn-结合的抗-IGF-1R抗体及其在血管性眼病治疗中的用途
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
KR102266819B1 (ko) 2013-04-29 2021-06-18 에프. 호프만-라 로슈 아게 Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
MY192404A (en) * 2013-05-02 2022-08-19 Hoffmann La Roche Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate
MY181960A (en) * 2013-05-02 2021-01-15 Hoffmann La Roche Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate
MX380520B (es) 2013-05-20 2025-03-12 Genentech Inc Anticuerpos receptores de antitransferina y métodos de uso.
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
CA2915665C (en) 2013-08-01 2020-07-28 Five Prime Therapeutics, Inc. Afucosylated anti-fgfr2iiib antibodies
EP3038657A2 (en) 2013-08-28 2016-07-06 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
AU2014317889B2 (en) 2013-09-06 2020-03-05 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
CA2922889A1 (en) 2013-09-17 2015-03-26 Genentech, Inc. Methods of using anti-lgr5 antibodies
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
EP3733244A1 (en) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015054691A2 (en) 2013-10-11 2015-04-16 The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services Tem8 antibodies and their use
CA2922912A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
CA2926084A1 (en) 2013-10-11 2015-04-16 Genentech, Inc. Nsp4 inhibitors and methods of use
MX2016004802A (es) 2013-10-18 2016-07-18 Genentech Inc Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
CA2924873A1 (en) 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
DK3063275T3 (da) 2013-10-31 2019-11-25 Resolve Therapeutics Llc Terapeutiske nuklease-albumin-fusioner og fremgangsmåder
KR102399292B1 (ko) 2013-11-21 2022-05-17 에프. 호프만-라 로슈 아게 항-알파-시누클레인 항체 및 사용 방법
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
CA2930886C (en) 2013-12-09 2024-05-21 Christopher R. Bebbington Anti-siglec-8 antibodies and methods of use thereof
AU2014362238A1 (en) 2013-12-13 2016-06-09 Genentech, Inc. Anti-CD33 antibodies and immunoconjugates
CN105934253A (zh) 2013-12-17 2016-09-07 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法
JP6449295B2 (ja) 2013-12-17 2019-01-09 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体および使用方法
KR20160099092A (ko) 2013-12-17 2016-08-19 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
WO2015095410A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
EP3089758B1 (en) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
KR20160104628A (ko) 2014-01-03 2016-09-05 에프. 호프만-라 로슈 아게 이중특이성 항-합텐/항-혈액뇌장벽 수용체 항체, 그의 복합체 및 혈액뇌장벽 셔틀로서 그의 용도
CN111057147B (zh) 2014-01-06 2023-11-10 豪夫迈·罗氏有限公司 单价血脑屏障穿梭模块
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
MX2016009515A (es) 2014-01-24 2016-10-26 Genentech Inc Metodos para utilizar anticuerpos anti-steap1 e inmunoconjugados.
US20170044232A1 (en) 2014-02-04 2017-02-16 Genentech, Inc. Mutant smoothened and methods of using the same
BR112016018205A8 (pt) 2014-02-08 2018-04-17 Genentech Inc métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
JP6685912B2 (ja) 2014-02-08 2020-04-22 ジェネンテック， インコーポレイテッド アルツハイマー病治療方法
SG10201808259TA (en) 2014-02-12 2018-10-30 Genentech Inc Anti-jagged1 antibodies and methods of use
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
CA2939931C (en) 2014-02-28 2025-04-22 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8
HRP20211748T1 (hr) 2014-03-14 2022-02-18 F. Hoffmann - La Roche Ag Postupci i sastavi za sekreciju heterolognih polipeptida
CN106103478B (zh) 2014-03-21 2020-04-03 豪夫迈·罗氏有限公司 抗体体内半寿期的体外预测
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015148531A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
EP3129767B1 (en) 2014-03-27 2021-09-01 Academia Sinica Reactive labelling compounds and uses thereof
JP6588461B2 (ja) 2014-03-31 2019-10-09 ジェネンテック， インコーポレイテッド 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
HUE046767T2 (hu) 2014-03-31 2020-03-30 Hoffmann La Roche Anti-OX40 antitestek és alkalmazási eljárások
KR20160143808A (ko) 2014-04-11 2016-12-14 메디뮨 엘엘씨 이중특이적 her2 항체
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
MX2016015162A (es) 2014-05-22 2017-03-03 Genentech Inc Anticuerpos anti - gpc3 e inmunoconjugados.
RU2016144405A (ru) 2014-05-23 2018-06-26 Дженентек, Инк. MiT БИОМАРКЕРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US20150344585A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
TWI679020B (zh) 2014-05-27 2019-12-11 中央研究院 抗ｈｅｒ２醣抗體及其用途
KR20170010003A (ko) 2014-05-27 2017-01-25 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
EP3148581B1 (en) 2014-05-30 2019-10-09 Henlius Biotech Co., Ltd. Anti-epidermal growth factor receptor (egfr) antibodies
CN106459202A (zh) 2014-06-11 2017-02-22 豪夫迈·罗氏有限公司 抗LgR5抗体及其用途
US20230190750A1 (en) 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
RU2705299C2 (ru) 2014-06-26 2019-11-06 Ф. Хоффманн-Ля Рош Аг Антитела против 5-бром-2'-дезоксиуридина и способы применения
CA2954868C (en) 2014-07-11 2023-08-29 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
EP3166627A1 (en) 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition
JP6464255B2 (ja) 2014-08-04 2019-02-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性ｔ細胞活性化抗原結合分子
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
DK3186284T3 (da) 2014-08-28 2022-05-09 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
EP3191500A4 (en) 2014-09-08 2018-04-11 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
CN114181312A (zh) * 2014-09-10 2022-03-15 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体
AU2015314744A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Anti-CLL-1 antibodies and immunoconjugates
EP3191518B1 (en) 2014-09-12 2020-01-15 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
ES2830385T3 (es) 2014-09-12 2021-06-03 Genentech Inc Anticuerpos e inmunoconjugados anti-HER2
SG11201701821QA (en) 2014-09-15 2017-04-27 Genentech Inc Antibody formulations
HK1243629A1 (zh) 2014-09-17 2018-07-20 基因泰克公司 包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
US9732148B2 (en) 2014-10-16 2017-08-15 Genentech, Inc. Anti-α-synuclein antibodies and methods of use
AU2015336931B2 (en) 2014-10-23 2021-04-29 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
WO2016070001A1 (en) 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
AU2015343339A1 (en) 2014-11-03 2017-06-15 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment
SG11201703448QA (en) 2014-11-03 2017-05-30 Genentech Inc Assays for detecting t cell immune subsets and methods of use thereof
KR20170080675A (ko) 2014-11-05 2017-07-10 제넨테크, 인크. 항-fgfr2/3 항체 및 이의 이용 방법
KR20170078677A (ko) 2014-11-06 2017-07-07 에프. 호프만-라 로슈 아게 Fcrn-결합이 개질된 fc-영역 변이체 및 이의 사용 방법
JP6576456B2 (ja) 2014-11-06 2019-09-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 修飾されたＦｃＲｎ結合特性およびプロテインＡ結合特性を有するＦｃ領域変種
SG11201703376QA (en) 2014-11-06 2017-05-30 Genentech Inc Combination therapy comprising ox40 binding agonists and tigit inhibitors
CR20170240A (es) 2014-11-10 2018-04-03 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos
WO2016077369A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Animal model for nephropathy and agents for treating the same
EP3224275B1 (en) 2014-11-14 2020-03-04 F.Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer
WO2016077789A1 (en) 2014-11-14 2016-05-19 The Usa, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
CN106999583A (zh) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
WO2016081639A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
EA201791121A1 (ru) 2014-11-20 2018-04-30 Ф. Хоффманн-Ля Рош Аг Активирующие т-клетки биспецифические антигенсвязывающие молекулы против folri и cd3
EP3221355B1 (en) 2014-11-20 2020-10-07 F.Hoffmann-La Roche Ag Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists
DK3221357T3 (da) 2014-11-20 2020-08-10 Hoffmann La Roche Fælles letkæder og fremgangsmåder til anvendelse
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
CN107108739B (zh) 2014-12-05 2022-01-04 豪夫迈·罗氏有限公司 抗CD79b抗体和使用方法
EP3230317A2 (en) 2014-12-10 2017-10-18 F. Hoffmann-La Roche AG Blood brain barrier receptor antibodies and methods of use
RS62749B1 (sr) 2014-12-19 2022-01-31 Chugai Pharmaceutical Co Ltd Anti-c5 antitela i načini njihove upotrebe
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
CN113956354A (zh) 2015-01-22 2022-01-21 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法
AU2015378564A1 (en) 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
AU2016215227A1 (en) 2015-02-04 2017-09-21 Assistance Publique-Hopitaux De Paris Mutant smoothened and methods of using the same
CA2974547A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof
KR20170140180A (ko) 2015-02-24 2017-12-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
WO2016149276A1 (en) 2015-03-16 2016-09-22 Genentech, Inc. Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
EP3271389B8 (en) 2015-03-20 2020-04-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to gp120 and their use
PH12021552158A1 (en) 2015-03-23 2022-05-02 Jounce Therapeutics Inc Antibodies to icos
SI3274370T1 (sl) 2015-03-23 2020-02-28 Bayer Pharma Aktiengesellschaft Protitelesa proti CEACAM6 in njihova uporaba
CN114456272A (zh) 2015-04-03 2022-05-10 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
CN107810197B (zh) 2015-04-24 2022-10-25 豪夫迈·罗氏有限公司 鉴定包含结合多肽的细菌的方法
JP6434135B2 (ja) * 2015-04-30 2018-12-05 富士フイルム株式会社 装飾シート
HK1252158A1 (zh) 2015-05-01 2019-05-17 Genentech, Inc. 掩蔽抗cd3抗体和使用方法
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
HK1248577A1 (zh) * 2015-05-11 2018-10-19 F. Hoffmann-La Roche Ag 治疗狼疮性肾炎的组合物和方法
KR20180008449A (ko) 2015-05-12 2018-01-24 제넨테크, 인크. 암에 대한 치료 및 진단 방법
ES2789500T5 (es) 2015-05-29 2023-09-20 Hoffmann La Roche Procedimientos terapéuticos y de diagnóstico para el cáncer
CN107771182A (zh) 2015-05-29 2018-03-06 豪夫迈·罗氏有限公司 人源化抗埃博拉病毒糖蛋白抗体和使用方法
HK1249016A1 (zh) 2015-06-02 2018-10-26 豪夫迈‧罗氏有限公司 使用抗il-34抗体治疗神经疾病的组合物和方法
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
BR112017025998A2 (pt) 2015-06-04 2018-08-14 Ospedale San Raffaele Srl inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit
WO2016193496A1 (en) 2015-06-04 2016-12-08 Ospedale San Raffaele Srl Igfbp3 and uses thereof
CA2986942C (en) 2015-06-05 2025-07-22 Ac Immune Sa Anti-tau antibodies and their methods of use
CA2985483A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies
KR20180025888A (ko) 2015-06-08 2018-03-09 제넨테크, 인크. 항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
AR104987A1 (es) 2015-06-15 2017-08-30 Genentech Inc Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
PT3310814T (pt) 2015-06-16 2023-10-02 H Hoffnabb La Roche Ag Anticorpos humanizados e de afinidade amadurecida para fcrh5 e métodos de utilização
JP2018526972A (ja) 2015-06-16 2018-09-20 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体及び使用方法
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
HK1254432A1 (zh) 2015-06-17 2019-07-19 Allakos Inc. 用於治疗纤维性疾病的方法和组合物
CN107771076A (zh) 2015-06-17 2018-03-06 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
HRP20251150T1 (hr) 2015-06-17 2025-12-05 F. Hoffmann - La Roche Ag Anti-her2 protutijela i postupci uporabe
WO2016207091A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
JP6811733B2 (ja) * 2015-06-24 2021-01-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト リンパ腫又は白血病におけるリンパ球増加症を誘導することにおける使用のためのヒトｃｓｆ−１ｒに対する抗体
MY180297A (en) 2015-06-24 2020-11-27 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
US10906971B2 (en) 2015-06-26 2021-02-02 Sanofi Biotechnology SAS Monoclonal anti-IL-1RAcP antibodies
MX2017016645A (es) 2015-06-29 2018-11-09 Genentech Inc Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
EP3514174B1 (en) 2015-06-29 2021-03-31 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP6914919B2 (ja) 2015-08-28 2021-08-04 ジェネンテック， インコーポレイテッド 抗ヒプシン抗体及びその使用
CA2999369C (en) 2015-09-22 2023-11-07 Spring Bioscience Corporation Anti-ox40 antibodies and diagnostic uses thereof
TWI748962B (zh) 2015-09-23 2021-12-11 美商建南德克公司 抗ｖｅｇｆ抗體之最佳化變異體
MX390255B (es) 2015-09-24 2025-03-20 Abvitro Llc Composiciones de anticuerpo de virus de inmunodeficiencia humana (vih) y metodos de uso
LT3353210T (lt) 2015-09-25 2025-01-27 F. Hoffmann-La Roche Ag Antikūnai prieš tigit ir jų naudojimo būdai
US10358497B2 (en) 2015-09-29 2019-07-23 Amgen Inc. Methods of treating cardiovascular disease with an ASGR inhibitor
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
AR106201A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche Moléculas biespecíficas de unión a antígeno activadoras de células t
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
PL3356411T3 (pl) 2015-10-02 2021-12-06 F. Hoffmann-La Roche Ag Przeciwciała dwuswoiste swoiste dla PD1 i TIM3
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
CN115594765A (zh) 2015-10-02 2023-01-13 豪夫迈·罗氏有限公司（Ch） 对共刺激性tnf受体特异性的双特异性抗体
WO2017060144A1 (en) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory tnf receptor
CA2997809A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
HK1258249A1 (zh) 2015-10-22 2019-11-08 震动疗法股份有限公司 用於测定icos表达的基因标志
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
CA3000048A1 (en) 2015-10-29 2017-05-04 F. Hoffmann-La Roche Ag Anti-variant fc-region antibodies and methods of use
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
JP6750010B2 (ja) 2015-10-30 2020-09-02 ジェネンテック， インコーポレイテッド 抗ＨｔｒＡ１抗体及びその使用方法
EP4011911A1 (en) 2015-11-03 2022-06-15 The United States of America as represented by The Secretary Department of Health and Human Services Neutralizing antibodies to hiv-1 gp41 and their use
JP6998869B2 (ja) 2015-11-08 2022-02-04 ジェネンテック， インコーポレイテッド 多重特異性抗体のスクリーニング方法
WO2017091580A1 (en) 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors
IL313608A (en) * 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
JP6142069B1 (ja) 2015-12-18 2017-06-07 中外製薬株式会社 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
SG10201709415WA (en) 2015-12-18 2017-12-28 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
CN108368179B (zh) 2016-01-08 2022-08-23 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
CN108602883A (zh) 2016-01-20 2018-09-28 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
AU2017225854B2 (en) 2016-02-29 2020-11-19 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
WO2017148879A1 (en) * 2016-03-01 2017-09-08 F. Hoffmann-La Roche Ag Obinutuzumab and rituximab variants having reduced adcp
TW201808978A (zh) 2016-03-08 2018-03-16 中央研究院 N-聚醣及其陣列之模組化合成方法
MX2018010546A (es) 2016-03-15 2019-02-20 Chugai Pharmaceutical Co Ltd Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3).
HUE061946T2 (hu) 2016-03-22 2023-09-28 Hoffmann La Roche Proteáz-aktivált T-sejt bispecifikus molekulák
EP4273551A3 (en) 2016-03-25 2024-01-17 F. Hoffmann-La Roche AG Multiplexed total antibody and antibody-conjugated drug quantification assay
CA3016035A1 (en) 2016-03-31 2017-10-05 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
WO2017180864A1 (en) 2016-04-14 2017-10-19 Genentech, Inc. Anti-rspo3 antibodies and methods of use
JP2019515670A (ja) 2016-04-15 2019-06-13 ジェネンテック， インコーポレイテッド がんをモニタリングし治療するための方法
JP6735355B2 (ja) 2016-04-15 2020-08-05 バイオアトラ、エルエルシー 抗Ａｘｌ抗体、抗体断片およびそれらの免疫コンジュゲートならびにそれらの使用
AU2017250296A1 (en) 2016-04-15 2018-11-01 Genentech, Inc. Methods for monitoring and treating cancer
BR112018069890A2 (pt) 2016-05-02 2019-02-05 Hoffmann La Roche polipeptídio de fusão que se liga de forma específica a um alvo, polipeptídio de fusão dimérico, ácido nucleico isolado, par de ácidos nucleicos isolados, célula hospedeira, método para produzir um polipeptídio de fusão, imunoconjugado, formulação farmacêutica, polipeptídio de fusão e uso do polipeptídio de fusão
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
WO2017194442A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
CN109071640B (zh) 2016-05-11 2022-10-18 豪夫迈·罗氏有限公司 经修饰抗生腱蛋白抗体及使用方法
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
TW202434312A (zh) 2016-05-13 2024-09-01 美商拜奧亞特拉公司 抗-ror2抗體、抗體片段、其免疫結合物及其用途
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
AU2018276419A1 (en) 2016-06-02 2019-10-17 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
EP3257866A1 (en) 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
EP3472200A4 (en) 2016-06-17 2020-04-01 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE THEREOF
WO2017223405A1 (en) 2016-06-24 2017-12-28 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
US11547748B2 (en) * 2016-06-30 2023-01-10 Hoffmann-La Roche Inc. Adoptive t-cell therapy
EP3478830B1 (en) 2016-07-01 2024-04-10 Resolve Therapeutics, LLC Optimized binuclease fusions and methods
CN109415435B (zh) 2016-07-04 2024-01-16 豪夫迈·罗氏有限公司 新型抗体形式
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
EP3492496A4 (en) 2016-07-29 2020-07-29 Chugai Seiyaku Kabushiki Kaisha BISPECIFIC ANTIBODIES PRESENTING AN INCREASED ALTERNATIVE FUNCTIONAL ACTIVITY OF COFACTOR FVIII
WO2018023100A2 (en) 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Anti-idiotypic antibodies and related methods
IL264626B (en) 2016-08-05 2022-07-01 Chugai Pharmaceutical Co Ltd Composition for prophylaxis or treatment of il-8 related diseases
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
CN107384932B (zh) 2016-08-31 2020-10-20 北京天广实生物技术股份有限公司 抗人cd20人源化单克隆抗体mil62、其制备方法及用途
CA3035081A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
US11168148B2 (en) 2016-09-07 2021-11-09 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN109689682B (zh) 2016-09-19 2022-11-29 豪夫迈·罗氏有限公司 基于补体因子的亲和层析
NZ790629A (en) 2016-09-23 2025-11-28 Genentech Inc Uses of il-13 antagonists for treating atopic dermatitis
EP3519437B1 (en) 2016-09-30 2021-09-08 F. Hoffmann-La Roche AG Bispecific antibodies against p95her2
EP3519433A1 (en) 2016-10-03 2019-08-07 Juno Therapeutics, Inc. Hpv-specific binding molecules
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
MX2019003934A (es) 2016-10-06 2019-07-10 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
JP7086066B2 (ja) 2016-11-02 2022-06-17 ジョンス セラピューティクス， インコーポレイテッド Ｐｄ－１に対する抗体及びその使用
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
KR102221364B1 (ko) 2016-11-21 2021-03-04 쿠레아브 게엠베하 항-gp73　항체　및　면역접합체
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
KR20230146126A (ko) 2016-12-07 2023-10-18 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
AU2017375946A1 (en) 2016-12-12 2019-06-20 Genentech, Inc. Methods of treating cancer using anti-PD-l1 antibodies and antiandrogens
MX2019006955A (es) 2016-12-19 2019-08-01 Hoffmann La Roche Terapia de combinacion con agonistas de 4-1bb orientados (cd137).
EP3559034B1 (en) 2016-12-20 2020-12-02 H. Hoffnabb-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
EP3565843A1 (en) 2017-01-03 2019-11-13 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
US11274157B2 (en) 2017-01-12 2022-03-15 Eureka Therapeutics, Inc. Constructs targeting histone H3 peptide/MHC complexes and uses thereof
MA47459A (fr) 2017-02-10 2019-12-18 Hoffmann La Roche Anticorps anti-tryptase, compositions les contenant et leurs utilisations
WO2018148660A1 (en) 2017-02-10 2018-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
PL3589754T3 (pl) 2017-03-01 2023-10-09 F. Hoffmann-La Roche Ag Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
MX2019011141A (es) 2017-03-22 2019-11-05 Genentech Inc Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares.
SG10201911225WA (en) 2017-03-28 2020-01-30 Genentech Inc Methods of treating neurodegenerative diseases
CN110573528B (zh) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
JP7205995B2 (ja) 2017-03-29 2023-01-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激性ｔｎｆ受容体に対する二重特異性抗原結合分子
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
MA49039A (fr) 2017-04-04 2020-02-12 Hoffmann La Roche Nouvelles molécules bispécifiques de liaison à l'antigène capables de se lier spécifiquement à cd40 et à fap
IL268527B2 (en) 2017-04-05 2024-03-01 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
CN110770255B (zh) 2017-04-11 2025-07-01 因荷布瑞克斯生物科学公司 具有受限cd3结合的多特异性多肽构建体及其使用方法
WO2018191660A1 (en) 2017-04-14 2018-10-18 Genentech, Inc. Diagnostic and therapeutic methods for cancer
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
KR20190141686A (ko) 2017-04-21 2019-12-24 제넨테크, 인크. 질환 치료를 위한 klk5 길항제의 용도
WO2018200586A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
BR112019022515A2 (pt) 2017-04-27 2020-06-16 Tesaro, Inc. Agentes de anticorpo direcionados contra o gene 3 de ativação linfocitária (lag-3) e usos dos mesmos
EP3618868A4 (en) 2017-05-05 2021-02-24 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
LT3624837T (lt) 2017-05-16 2025-10-10 Anti-fgfr2 antikūnai derinyje su chemoterapijos agentais vėžio gydymui
CN110945028B (zh) 2017-07-10 2023-09-08 国际药物发展生物技术公司 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤
MX2020000604A (es) 2017-07-21 2020-09-10 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
CN110869391A (zh) 2017-07-26 2020-03-06 豪夫迈·罗氏有限公司 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法
JP7122370B2 (ja) 2017-07-26 2022-08-19 フォーティ セブン， インコーポレイテッド 抗ｓｉｒｐ－アルファ抗体及び関連方法
UA126204C2 (uk) 2017-08-08 2022-08-31 Ф. Хоффманн-Ля Рош Аг Лікування нової підгрупи пацієнтів із dlbcl за допомогою обінутузумабу
CN107881160A (zh) * 2017-08-11 2018-04-06 百奥泰生物科技(广州)有限公司 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
AU2018321359B2 (en) 2017-08-22 2023-11-30 Sanabio, Llc Soluble interferon receptors and uses thereof
ES2991804T3 (es) * 2017-09-19 2024-12-04 Tillotts Pharma Ag Variantes de anticuerpos
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
BR112020006643A2 (pt) 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
EP3694890A4 (en) 2017-10-12 2021-11-03 Immunowake Inc. VEGFR ANTIBODY LIGHT CHAIN FUSION PROTEIN
CN120983618A (zh) 2017-10-19 2025-11-21 豪夫迈·罗氏有限公司 用奥滨尤妥珠单抗对cd20阳性b细胞淋巴瘤的治疗
MX2020004243A (es) 2017-11-01 2020-09-25 Juno Therapeutics Inc Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
BR112020007630A2 (pt) 2017-11-01 2020-11-17 F. Hoffmann-La Roche Ag anticorpo biespecífico ox40, produto farmacêutico, composição farmacêutica e anticorpos biespecíficos anti-fap/ anti-ox40
JP2021500902A (ja) 2017-11-01 2021-01-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
EP3703821A2 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Bispecific 2+1 contorsbodies
TW201923089A (zh) 2017-11-06 2019-06-16 美商建南德克公司 癌症之診斷及治療方法
JP7731196B2 (ja) 2017-11-14 2025-08-29 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
WO2019108639A1 (en) 2017-12-01 2019-06-06 Pfizer Inc. Anti-cxcr5 antibodies and compositions and uses thereof
CN111212660A (zh) 2017-12-14 2020-05-29 豪夫迈·罗氏有限公司 Cea cd3双特异性抗体和pd-1轴结合拮抗剂在治疗癌症的剂量方案中的用途
EP3724225A1 (en) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
KR20200103706A (ko) 2017-12-22 2020-09-02 조운스 테라퓨틱스, 인크. Lilrb2에 대한 항체
US20190211098A1 (en) 2017-12-22 2019-07-11 Genentech, Inc. Use of pilra binding agents for treatment of a disease
JP7369127B2 (ja) 2017-12-28 2023-10-25 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体
CA3078849A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against pd-l1
EP3724223A1 (en) 2018-01-02 2020-10-21 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
CN118955720A (zh) 2018-01-04 2024-11-15 伊科尼克治疗公司 抗组织因子抗体、抗体-药物缀合物及相关方法
JP7426724B2 (ja) 2018-01-05 2024-02-02 エイシー イミューン ソシエテ アノニム ミスフォールドされたｔｄｐ－４３結合分子
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
TWI802633B (zh) 2018-01-15 2023-05-21 大陸商南京傳奇生物科技有限公司 針對pd-1之單域抗體及其變異體
WO2019143636A1 (en) 2018-01-16 2019-07-25 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
LT3743088T (lt) 2018-01-26 2022-12-27 F. Hoffmann-La Roche Ag Il-22 fc kompozicijos ir jų naudojimo būdai
TWI835772B (zh) 2018-01-26 2024-03-21 美商建南德克公司 Il-22fc融合蛋白及使用方法
AU2019214183B2 (en) 2018-02-01 2022-04-07 Innovent Biologics (Suzhou) Co., Ltd. Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
MA51793A (fr) 2018-02-08 2020-12-16 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation
MA51741A (fr) 2018-02-09 2021-05-19 Hoffmann La Roche Procédés thérapeutiques et de diagnostic pour des maladies inflammatoires médiées par des mastocytes
WO2019158645A1 (en) 2018-02-14 2019-08-22 Abba Therapeutics Ag Anti-human pd-l2 antibodies
SG11202007694UA (en) 2018-02-21 2020-09-29 Genentech Inc DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
AU2019226034A1 (en) 2018-02-21 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 Env and their use
TWI874309B (zh) 2018-02-26 2025-03-01 美商建南德克公司 用於抗tigit拮抗劑抗體及抗pd-l1拮抗劑抗體治療之投藥
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
BR112020015568A2 (pt) 2018-03-13 2020-12-29 F. Hoffmann-La Roche Ag Agonista de 4-1bb (cd137), produto farmacêutico, composição farmacêutica, uso de uma combinação de um agonista de 4-1bb e método para tratar ou retardar a progressão do câncer
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
SG11202006217YA (en) 2018-03-14 2020-07-29 Beijing Xuanyi Pharmasciences Co Ltd Anti-claudin 18.2 antibodies
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
WO2019183040A1 (en) 2018-03-21 2019-09-26 Five Prime Therapeutics, Inc. ANTIBODIES BINDING TO VISTA AT ACIDIC pH
KR102876940B1 (ko) 2018-03-30 2025-10-24 난징 레전드 바이오테크 씨오., 엘티디. Lag-3에 대한 단일-도메인 항체 및 이의 용도
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
AU2019249209A1 (en) 2018-04-05 2020-10-15 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
MX2020010638A (es) 2018-04-11 2021-01-08 Inhibrx Inc Constructos de polipeptidos multiespecificos que tienen union a cd3 restringida y metodos y usos relacionados.
EP3774900A1 (en) 2018-04-13 2021-02-17 F. Hoffmann-La Roche AG Her2-targeting antigen binding molecules comprising 4-1bbl
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
CA3102230A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
JP7372237B2 (ja) 2018-06-04 2023-10-31 中外製薬株式会社 細胞質内での半減期が変化した抗原結合分子
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
AU2019288136A1 (en) 2018-06-18 2021-01-07 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
US12275797B2 (en) 2018-06-22 2025-04-15 Genmab Holding B.V. Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
AU2019288728A1 (en) 2018-06-23 2021-01-14 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP2021528988A (ja) 2018-07-04 2021-10-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規の二重特異性アゴニスト４−１ｂｂ抗原結合分子
WO2020014139A1 (en) 2018-07-09 2020-01-16 Millennium Pharmaceuticals, Inc. Administration of sumo-activating enzyme inhibitor and anti-cd20 antibodies
TWI819024B (zh) 2018-07-09 2023-10-21 美商戊瑞治療有限公司 結合至ｉｌｔ４的抗體
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CA3104536A1 (en) 2018-07-11 2020-01-16 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
JP2021530502A (ja) 2018-07-18 2021-11-11 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト、代謝拮抗剤、及びプラチナ製剤で肺がんを治療する方法
WO2020018879A1 (en) 2018-07-20 2020-01-23 Surface Oncology, Inc. Anti-cd112r compositions and methods
JP7651450B2 (ja) 2018-07-24 2025-03-26 インヒブルクス バイオサイエンシズ インコーポレイテッド 制約されたｃｄ３結合ドメインおよび受容体結合領域を含有する多重特異性ポリペプチド構築物ならびにそれを使用する方法
KR20210040989A (ko) 2018-08-03 2021-04-14 추가이 세이야쿠 가부시키가이샤 서로 연결된 2개의 항원 결합 도메인을 포함하는 항원 결합 분자
CA3051549A1 (en) 2018-08-09 2020-02-09 Regeneron Pharmaceuticals, Inc. Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
WO2020032230A1 (ja) 2018-08-10 2020-02-13 中外製薬株式会社 抗ｃｄ１３７抗原結合分子およびその使用
WO2020037258A1 (en) 2018-08-17 2020-02-20 Ab Studio Inc. Catabodies and methods of use thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CN112789293B (zh) 2018-09-10 2024-05-10 南京传奇生物科技有限公司 针对cll1的单结构域抗体及其构建体
AU2019342099A1 (en) 2018-09-19 2021-04-08 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2020061349A1 (en) 2018-09-21 2020-03-26 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
EP3856764A4 (en) 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
WO2020070041A1 (en) 2018-10-01 2020-04-09 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-fap clone 212
JP2022511396A (ja) 2018-10-01 2022-01-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ４０への三価結合を伴う二重特異性抗原結合分子
EP3632929A1 (en) 2018-10-02 2020-04-08 Ospedale San Raffaele S.r.l. Antibodies and uses thereof
MY208925A (en) 2018-10-05 2025-06-11 Five Prime Therapeutics Inc Anti-fgfr2 antibody formulations
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3115285A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
CA3116324A1 (en) 2018-10-18 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
CA3118312A1 (en) * 2018-10-29 2020-05-07 Tigatx, Inc. Compositions and methods comprising iga antibody constructs
CA3117856A1 (en) 2018-10-31 2020-05-07 Bayer Aktiengesellschaft Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
WO2020102555A1 (en) 2018-11-16 2020-05-22 Memorial Sloan Kettering Cancer Center Antibodies to mucin-16 and methods of use thereof
AU2019388584B2 (en) 2018-11-27 2024-02-15 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing Granulocyte-Macrophage Colony Stimulating Factor Receptor alpha and uses thereof
CN113260633A (zh) 2018-12-05 2021-08-13 豪夫迈·罗氏有限公司 用于癌症免疫疗法的诊断方法和组合物
KR20210100668A (ko) 2018-12-06 2021-08-17 제넨테크, 인크. 항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
EP3883609A2 (en) 2018-12-20 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
JP2022514290A (ja) 2018-12-20 2022-02-10 ジェネンテック， インコーポレイテッド 改変抗体ｆｃおよび使用方法
US20200223925A1 (en) 2018-12-21 2020-07-16 Hoffmann-La Roche Inc. Tumor-targeted superagonistic cd28 antigen binding molecules
SG11202105093RA (en) 2018-12-21 2021-06-29 Hoffmann La Roche Tumor-targeted agonistic cd28 antigen binding molecules
WO2020139926A2 (en) 2018-12-26 2020-07-02 Akrevia Therapeutics Inc. Anti-ctla4 antibodies and methods of use thereof
EP3902830A1 (en) 2018-12-30 2021-11-03 F. Hoffmann-La Roche AG Anti-rabbit cd19 antibodies and methods of use
AU2020208193A1 (en) 2019-01-14 2021-07-29 BioNTech SE Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
WO2020148379A1 (en) 2019-01-17 2020-07-23 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
EP3914623A4 (en) 2019-01-23 2022-11-23 Tayu Huaxia Biotech Medical Group Co., Ltd. ANTI-PD-L1 DIABODIES AND THEIR USE
US20220089770A1 (en) 2019-01-24 2022-03-24 Chugai Seiyaku Kabushiki Kaisha Novel cancer antigens and antibodies of said antigens
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
AR119683A1 (es) 2019-01-29 2022-01-05 Juno Therapeutics Inc Anticuerpos y receptores de antígeno quimérico específicos para receptor huérfano 1 similar a receptor de tirosina quinasa (ror1)
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
WO2020172571A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2020176748A1 (en) 2019-02-27 2020-09-03 Genentech, Inc. Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
TWI892981B (zh) 2019-03-08 2025-08-11 美商建南德克公司 用於偵測且量化膜相關蛋白之方法
KR20210141555A (ko) 2019-03-14 2021-11-23 제넨테크, 인크. Her2xcd3 이중특이적 항체 및 항-her2 mab를 병용한 암의 치료
EP3952996A1 (en) 2019-04-12 2022-02-16 F. Hoffmann-La Roche AG Bispecific antigen binding molecules comprising lipocalin muteins
KR20220004087A (ko) 2019-04-19 2022-01-11 추가이 세이야쿠 가부시키가이샤 항체 개변 부위 인식 키메라 수용체
TW202043291A (zh) 2019-04-19 2020-12-01 美商建南德克公司 抗mertk抗體及使用方法
EP3962523A2 (en) 2019-05-03 2022-03-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
CA3133821A1 (en) 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody
KR20220007136A (ko) 2019-05-14 2022-01-18 제넨테크, 인크. 소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
CN114008073B (zh) 2019-05-23 2025-08-12 Ac免疫有限公司 抗tdp-43结合分子及其用途
US20220324975A1 (en) * 2019-06-05 2022-10-13 Chugai Seiyaku Kabushiki Kaisha Antibody cleavage site binding molecule
JP2022538075A (ja) 2019-06-26 2022-08-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体結合ｃｅａ及び４－１ｂｂｌの融合
WO2020260326A1 (en) 2019-06-27 2020-12-30 F. Hoffmann-La Roche Ag Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
EA202290208A1 (ru) 2019-07-02 2022-03-25 Дзе Юнайтед Стейтс Оф Эмерика, Эз Репрезентед Бай Дзе Секретэри, Дипартмент Оф Хелт Энд Хьюман Сервисиз МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ EGFRvIII, И ИХ ПРИМЕНЕНИЕ
WO2021005009A1 (en) 2019-07-05 2021-01-14 Iomx Therapeutics Ag Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
BR112021026788A2 (pt) 2019-07-09 2022-05-10 Staidson Beijing Biopharmaceuticals Co Ltd Anticorpos que reconhecem especificamente pcrv de pseudomonas e usos dos mesmos
US20220267452A1 (en) 2019-07-12 2022-08-25 Chugai Seiyaku Kabushiki Kaisha Anti-mutation type fgfr3 antibody and use therefor
CN114641490B (zh) 2019-08-06 2023-06-06 新旭生技股份有限公司 结合至病理性tau种类的抗体及其用途
EP4028054B1 (en) 2019-09-12 2025-12-31 F. Hoffmann-La Roche AG COMPOUNDS AND METHODS FOR THE TREATMENT OF LUPUS NEPHRITIS
WO2021055698A1 (en) 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
MX2022003266A (es) 2019-09-20 2022-04-11 Genentech Inc Dosis para anticuerpos anti-triptasa.
CA3151406A1 (en) 2019-09-27 2021-04-01 Raymond D. Meng Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
JP7413519B2 (ja) 2019-10-18 2024-01-15 ジェネンテック， インコーポレイテッド びまん性大細胞型ｂ細胞リンパ腫を処置するための抗ｃｄ７９ｂ免疫抱合体の使用方法
CA3155922A1 (en) 2019-11-06 2021-05-14 Huang Huang Diagnostic and therapeutic methods for treatment of hematologic cancers
TWI895295B (zh) 2019-11-12 2025-09-01 美商方得生醫療公司 偵測編碼新生抗原之融合基因之方法
CN114651006A (zh) 2019-11-15 2022-06-21 恩瑟拉有限责任公司 Tmem219抗体及其治疗性用途
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
CA3154017A1 (en) 2019-11-21 2021-05-27 Giovanni AMABILE Igfbp3 antibodies and therapeutic uses thereof
MX2022006709A (es) 2019-12-06 2022-09-12 Juno Therapeutics Inc Anticuerpos antiidiotípicos para dominios de unión dirigidos a bcma y métodos y composiciones relacionadas.
EP4069742A1 (en) 2019-12-06 2022-10-12 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
TWI897903B (zh) 2019-12-13 2025-09-21 美商建南德克公司 抗ly6g6d抗體及其使用方法
US20230058982A1 (en) 2019-12-27 2023-02-23 Chugai Seiyaku Kabushiki Kaisha Anti-ctla-4 antibody and use thereof
CN113045655A (zh) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
JP2023509708A (ja) 2020-01-03 2023-03-09 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
MX2022008214A (es) 2020-01-09 2022-08-08 Hoffmann La Roche Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl.
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
MX2022009306A (es) 2020-01-29 2022-09-26 Inhibrx Inc Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
EP4096708A1 (en) 2020-01-31 2022-12-07 Genentech, Inc. Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
US20230078601A1 (en) 2020-01-31 2023-03-16 The Cleveland Clinic Foundation Anti-mullerian hormone receptor 2 antibodies and methods of use
TWI895351B (zh) 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
CR20220396A (es) 2020-02-14 2022-11-14 Jounce Therapeutics Inc Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
EP4093762A1 (en) 2020-02-20 2022-11-30 The United States of America, as represented by the Secretary, Department of Health and Human Services Epstein-barr virus monoclonal antibodies and uses thereof
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
CN115066440A (zh) 2020-02-28 2022-09-16 上海复宏汉霖生物技术股份有限公司 抗cd137构建体及其用途
JP7791826B2 (ja) 2020-02-28 2025-12-24 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
BR112022018254A2 (pt) 2020-03-13 2022-10-25 Genentech Inc Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo
CN117510630B (zh) 2020-03-19 2025-03-04 基因泰克公司 同种型选择性抗TGF-β抗体及使用方法
CN115867577A (zh) 2020-03-23 2023-03-28 基因泰克公司 用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物
US20230174656A1 (en) 2020-03-23 2023-06-08 Genentech, Inc. Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
EP4107184A1 (en) 2020-03-23 2022-12-28 Genentech, Inc. Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
WO2021194913A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CN115698717A (zh) 2020-04-03 2023-02-03 基因泰克公司 癌症的治疗和诊断方法
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
EP4139359A1 (en) 2020-04-24 2023-03-01 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
KR20230004520A (ko) 2020-04-27 2023-01-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 지단백(ａ)에 대한 이소형-비의존성 항체
WO2021222167A1 (en) 2020-04-28 2021-11-04 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
JP2023527962A (ja) 2020-05-03 2023-07-03 レヴィーナ （スジョウ） バイオファーマ カンパニー， リミテッド 抗ｔｒｏｐ２抗体を含む抗体薬物複合体（ａｄｃ）、かかるａｄｃを含む組成物、ならびにそれらを作製および使用する方法
EP4559477A3 (en) 2020-05-13 2025-08-13 Adagene AG Compositions and methods for treating cancer
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
WO2021238886A1 (en) 2020-05-27 2021-12-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
TW202210515A (zh) 2020-06-02 2022-03-16 美商當康生物科技有限公司 抗ｃｄ３９之構築體及其用途
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
CN115698719A (zh) 2020-06-12 2023-02-03 基因泰克公司 用于癌症免疫疗法的方法和组合物
CN115916182A (zh) 2020-06-16 2023-04-04 基因泰克公司 用于治疗三阴性乳腺癌的方法和组合物
JP2023531200A (ja) 2020-06-18 2023-07-21 ジェネンテック， インコーポレイテッド 抗ｔｉｇｉｔ抗体及びｐｄ－１軸結合アンタゴニストを用いた治療
KR20230025672A (ko) 2020-06-19 2023-02-22 에프. 호프만-라 로슈 아게 Cd3 및 cd19에 결합하는 항체
CN115702168A (zh) 2020-06-23 2023-02-14 豪夫迈·罗氏有限公司 靶向Her2的激动性CD28抗原结合分子
EP4172203A1 (en) 2020-06-25 2023-05-03 F. Hoffmann-La Roche AG Anti-cd3/anti-cd28 bispecific antigen binding molecules
EP4175668A1 (en) 2020-07-06 2023-05-10 iOmx Therapeutics AG Antibodies binding igv of igsf11 (vsig3) and uses thereof
EP4178529A1 (en) 2020-07-07 2023-05-17 F. Hoffmann-La Roche AG Alternative surfactants as stabilizers for therapeutic protein formulations
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN116783215A (zh) 2020-07-29 2023-09-19 当康生物技术有限责任公司 抗cd93构建体及其用途
JP2023536602A (ja) 2020-08-03 2023-08-28 ジェネンテック， インコーポレイテッド リンパ腫のための診断及び治療方法
KR20230095918A (ko) 2020-08-05 2023-06-29 주노 쎄러퓨티크스 인코퍼레이티드 Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법
KR20230042596A (ko) 2020-08-07 2023-03-28 제넨테크, 인크. Flt3 리간드 융합 단백질 및 이용 방법
JP2023537761A (ja) 2020-08-14 2023-09-05 エイシー イミューン ソシエテ アノニム ヒト化抗ｔｄｐ－４３結合分子およびその使用
WO2022043517A2 (en) 2020-08-27 2022-03-03 Cureab Gmbh Anti-golph2 antibodies for macrophage and dendritic cell differentiation
KR20230069171A (ko) 2020-09-15 2023-05-18 바이엘 악티엔게젤샤프트 신규 항-a2ap 항체 및 그의 용도
JP2023541921A (ja) 2020-09-17 2023-10-04 ジェネンテック， インコーポレイテッド Ｃｏｖｉｄ－１９肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験（ｅｍｐａｃｔａ）の結果
CN118126189A (zh) 2020-09-28 2024-06-04 安济盛生物医药有限公司 抗硬骨抑素构建体及其用途
AU2021358031A1 (en) 2020-10-05 2023-05-04 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CA3190782A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhibitors
CA3192306A1 (en) 2020-10-20 2022-04-28 Burkhard Ludewig Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
WO2022096536A1 (en) 2020-11-03 2022-05-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
AU2021374592A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
JP7762198B2 (ja) 2020-11-04 2025-10-29 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体及び抗ｃｄ７９ｂ抗体薬物コンジュゲートによる処置のための投与
EP4240766A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
EP4244254A1 (en) 2020-11-16 2023-09-20 F. Hoffmann-La Roche AG Combination therapy with fap-targeted cd40 agonists
CA3196844A1 (en) 2020-11-25 2022-06-02 Raphael Rozenfeld Tumor-specific cleavable linkers
WO2022116877A1 (en) 2020-12-02 2022-06-09 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
MX2023007846A (es) 2021-01-06 2023-07-07 Hoffmann La Roche Tratamiento conjunto que usa un anticuerpo biespecifico contra pd1-lag3 y un anticuerpo biespecifico de linfocitos t cd20.
WO2022162587A1 (en) 2021-01-27 2022-08-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
WO2022162203A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses
CN117120084A (zh) 2021-01-28 2023-11-24 维肯芬特有限责任公司 用于调节b细胞介导的免疫应答的方法和手段
AU2022212599A1 (en) 2021-01-28 2023-08-17 Universität Ulm Method and means for modulating b-cell mediated immune responses
CA3209136A1 (en) 2021-02-09 2022-08-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses
US20240117019A1 (en) 2021-02-09 2024-04-11 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
CA3208365A1 (en) 2021-02-15 2022-08-18 Chantal KUHN Cell therapy compositions and methods for modulating tgf-b signaling
EP4298123A2 (en) 2021-02-26 2024-01-03 Bayer Aktiengesellschaft Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
EP4301781A1 (en) 2021-03-01 2024-01-10 Xilio Development, Inc. Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
EP4301467A1 (en) 2021-03-01 2024-01-10 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
WO2022184082A1 (en) 2021-03-03 2022-09-09 Sorrento Therapeutics, Inc. Antibody-drug conjugates comprising an anti-bcma antibody
CN117715933A (zh) 2021-03-05 2024-03-15 当康生物技术有限责任公司 抗vista的构建体及其用途
BR112023018621A2 (pt) 2021-03-15 2023-10-24 Hoffmann La Roche Métodos para tratar nefrite lúpica, esgotar células b periféricas, kits para tratar nefrite lúpica e anticorpos anti-cd20 tipo ii
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
WO2022204724A1 (en) 2021-03-25 2022-09-29 Dynamicure Biotechnology Llc Anti-igfbp7 constructs and uses thereof
CN117396504A (zh) 2021-03-30 2024-01-12 拜耳公司 抗Sema3A抗体及其用途
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
AU2021443863A1 (en) 2021-04-30 2023-10-26 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
AU2022273063A1 (en) 2021-05-12 2023-11-23 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
US12384844B2 (en) 2021-05-14 2025-08-12 Genentech, Inc. Agonists of TREM2
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
AR126054A1 (es) 2021-06-04 2023-09-06 Chugai Pharmaceutical Co Ltd Anticuerpos anti-ddr2 y usos de estos
JP2024521579A (ja) 2021-06-09 2024-06-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療における使用のための特定のｂｒａｆ阻害剤（パラドックスブレーカー）とｐｄ－１軸結合アンタゴニストとの組み合わせ
WO2022261417A1 (en) 2021-06-11 2022-12-15 Genentech, Inc. Method for treating chronic obstructive pulmonary disease with an st2 antagonist
WO2022263638A1 (en) 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
WO2022266660A1 (en) 2021-06-17 2022-12-22 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
BR112023022992A2 (pt) 2021-06-25 2024-01-23 Chugai Pharmaceutical Co Ltd Anticorpo anti-ctla-4
EP4361176A4 (en) 2021-06-25 2025-03-12 Chugai Seiyaku Kabushiki Kaisha USE OF ANTI-CTLA-4 ANTIBODIES
WO2023283611A1 (en) 2021-07-08 2023-01-12 Staidson Biopharma Inc. Antibodies specifically recognizing tnfr2 and uses thereof
KR20240058075A (ko) 2021-07-14 2024-05-03 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 Cd40을 특이적으로 식별하는 항체 및 이의 응용
JP2024526880A (ja) 2021-07-22 2024-07-19 ジェネンテック， インコーポレイテッド 脳標的化組成物及びその使用方法
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
EP4384553A1 (en) 2021-08-13 2024-06-19 Genentech, Inc. Dosing for anti-tryptase antibodies
EP4388014A1 (en) 2021-08-19 2024-06-26 F. Hoffmann-La Roche AG Multivalent anti-variant fc-region antibodies and methods of use
AU2022332303A1 (en) 2021-08-27 2024-02-01 Genentech, Inc. Methods of treating tau pathologies
MX2024002611A (es) 2021-08-30 2024-05-29 Lassen Therapeutics 1 Inc Anticuerpos anti-il-11ra.
WO2023034750A1 (en) 2021-08-30 2023-03-09 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
KR20240058167A (ko) 2021-09-17 2024-05-03 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Sars-cov-2 중화 항체 동정을 위한 합성 인간화 라마 나노바디 라이브러리 및 이의 용도
US12441816B2 (en) 2021-09-21 2025-10-14 Qilu Puget Sound Biotherapeutics Corporation Heterodimeric Fc for making fusion proteins and bispecific antibodies
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
US20240404622A1 (en) 2021-10-08 2024-12-05 Chugai Seiyaku Kabushiki Kaisha Method for preparing prefilled syringe formulation
US20250251400A1 (en) 2021-11-05 2025-08-07 American Diagnostics & Therapy, Llc (Adxrx) Monoclonal Antibodies Against Carcinoembryonic Antigens, and Their Uses
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
MX2024005680A (es) 2021-11-16 2024-05-30 Genentech Inc Metodos y composiciones para tratar lupus eritematoso sistemico (sle) con mosunetuzumab.
CA3235206A1 (en) 2021-11-16 2023-05-25 Davide BASCO Novel molecules for therapy and diagnosis
CN116829179A (zh) 2021-12-06 2023-09-29 北京三诺佳邑生物技术有限责任公司 特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物
AU2022411573A1 (en) 2021-12-17 2024-06-27 Shanghai Henlius Biologics Co., Ltd. Anti-ox40 antibodies and methods of use
WO2023109900A1 (en) 2021-12-17 2023-06-22 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
EP4476251A1 (en) 2022-02-10 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Human monoclonal antibodies that broadly target coronaviruses
KR20240150774A (ko) 2022-02-16 2024-10-16 에이씨 이뮨 에스에이 인간화된 항-tdp-43 결합 분자 및 이의 용도
CN119095874A (zh) 2022-02-18 2024-12-06 乐天医药生技股份有限公司 抗程序性死亡配体1(pd-l1)抗体分子、编码多核苷酸及使用方法
US20250205350A1 (en) 2022-03-10 2025-06-26 Vivasor, Inc. Antibody-Drug Conjugates and Uses Thereof
CN119584984A (zh) 2022-03-23 2025-03-07 豪夫迈·罗氏有限公司 抗cd20/抗cd3双特异性抗体与化学疗法的组合治疗
KR20240163119A (ko) 2022-03-25 2024-11-18 상하이 헨리우스 바이오테크, 인크. 항-msln 항체 및 사용 방법
EP4499227A1 (en) 2022-03-26 2025-02-05 The United States of America, as represented by The Secretary, Department of Health and Human Services Bispecific antibodies to hiv-1 env and their use
WO2023192881A1 (en) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
CN119095880A (zh) 2022-03-28 2024-12-06 豪夫迈·罗氏有限公司 干扰素γ变体以及包含这些变体的抗原结合分子
EP4504780A1 (en) 2022-04-01 2025-02-12 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
IL316153A (en) 2022-04-08 2024-12-01 Ac Immune Sa Anti-tdp-43 binding molecules
JP2025512342A (ja) 2022-04-13 2025-04-17 ジェネンテック， インコーポレイテッド 治療用タンパク質の医薬組成物および使用方法
CA3255366A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
WO2023203177A1 (en) 2022-04-20 2023-10-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
CR20240526A (es) 2022-05-03 2025-01-10 Genentech Inc Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
CN119487065A (zh) 2022-05-09 2025-02-18 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
KR20250008898A (ko) 2022-05-11 2025-01-16 제넨테크, 인크. 항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) * 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
CN119856056A (zh) 2022-06-07 2025-04-18 基因泰克公司 用于确定包括抗pd-l1拮抗剂和抗tight拮抗剂抗体的肺癌治疗的疗效的方法
US20250382354A1 (en) 2022-06-08 2025-12-18 Institute For Research In Biomedicine (Irb) Cross-specific antibodies, uses and methods for discovery thereof
KR20250039386A (ko) 2022-07-13 2025-03-20 제넨테크, 인크. 항-fcrh5/항-cd3 이중특이적 항체를 이용한 치료를 위한 투약법
EP4558226A1 (en) 2022-07-19 2025-05-28 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
JP2025523845A (ja) 2022-07-19 2025-07-25 ジェネンテック， インコーポレイテッド 抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投薬
AU2023312054A1 (en) 2022-07-22 2025-01-23 Bristol-Myers Squibb Company Antibodies binding to human pad4 and uses thereof
WO2024020564A1 (en) 2022-07-22 2024-01-25 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
EP4565329A1 (en) 2022-08-01 2025-06-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024028731A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Transferrin receptor binding proteins for treating brain tumors
CA3263779A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. CD98 LINKAGE CONSTRUCTIONS FOR THE TREATMENT OF BRAIN TUMORS
EP4577578A1 (en) 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
JP2025529903A (ja) 2022-08-26 2025-09-09 ジュノー セラピューティクス インコーポレイテッド デルタ様リガンド３（ｄｌｌ３）に特異的な抗体およびキメラ抗原受容体
CN120153254A (zh) 2022-09-01 2025-06-13 基因泰克公司 膀胱癌的治疗和诊断方法
EP4584296A1 (en) 2022-09-07 2025-07-16 Dynamicure Biotechnology LLC Anti-vista constructs and uses thereof
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
CA3268115A1 (en) 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized Anti-IL-1R3 Antibodies and Methods of Use
WO2024064826A1 (en) 2022-09-22 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
CN119998321A (zh) 2022-09-27 2025-05-13 舒泰神（北京）生物制药股份有限公司 特异性识别light的抗体及其应用
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
WO2024083021A1 (zh) 2022-10-20 2024-04-25 北京三诺佳邑生物技术有限责任公司 特异性结合TRAIL或FasL的抗体组合以及双特异性抗体
TW202426505A (zh) 2022-10-25 2024-07-01 美商建南德克公司 癌症之治療及診斷方法
EP4612178A1 (en) 2022-11-03 2025-09-10 F. Hoffmann-La Roche AG Combination therapy with anti-cd19/anti-cd28 bispecific antibody
JP2025537137A (ja) 2022-11-04 2025-11-14 ギリアード サイエンシーズ， インコーポレイテッド 抗ｃｃｒ８抗体、化学療法及び免疫療法の組み合わせを使用する抗がん療法
KR20250099701A (ko) 2022-11-08 2025-07-02 제넨테크, 인크. 소아기 발병 특발성 신증후군의 치료 조성물 및 치료 방법
IL320220A (en) 2022-11-09 2025-06-01 Cis Biopharma Ag Antibodies against L1-CAM and their uses for diagnostic and therapeutic applications
WO2024108053A1 (en) 2022-11-17 2024-05-23 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
EP4624489A1 (en) 2022-11-25 2025-10-01 Chugai Seiyaku Kabushiki Kaisha Method for producing protein
EP4638491A1 (en) 2022-12-19 2025-10-29 The United States of America, as represented by The Secretary, Department of Health and Human Services Monoclonal antibodies for treating sars-cov-2 infection
EP4491230A1 (en) 2023-07-14 2025-01-15 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
KR20250129687A (ko) 2022-12-23 2025-08-29 아이오엠엑스 테라퓨틱스 아게 백혈구 면역글로불린 유사 수용체 서브패밀리 b1 (lilrb1) 및 lilrb2를 표적으로 하는 교차 특이적 항원 결합 단백질(abp), 이의 조합 및 용도
EP4646441A1 (en) 2023-01-06 2025-11-12 Lassen Therapeutics, Inc. Anti-il-11r alpha antibodies for treating thyroid eye disease
WO2024148243A1 (en) 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. Anti-il-18bp antibodies
EP4646432A1 (en) 2023-01-06 2025-11-12 Lassen Therapeutics, Inc. Anti-il-18bp antibodies
EP4676596A1 (en) 2023-03-08 2026-01-14 AC Immune SA Anti-tdp-43 binding molecules and uses thereof
EP4428159A1 (en) 2023-03-10 2024-09-11 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Melanoma targeting human antibodies and therapeutic uses thereof
EP4428158A1 (en) 2023-03-10 2024-09-11 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Lung cancer targeting human antibodies and therapeutic uses thereof
WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
CN121263432A (zh) 2023-04-12 2026-01-02 上海康抗生物技术有限公司 包含掩蔽型白介素12的多功能分子及使用方法
AU2024257248A1 (en) 2023-04-17 2025-11-06 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024233646A1 (en) 2023-05-10 2024-11-14 Genentech, Inc. Methods and compositions for treating cancer
WO2024243355A1 (en) 2023-05-24 2024-11-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
AR132805A1 (es) 2023-06-01 2025-07-30 Hoffmann La Roche Moléculas de unión al antígeno inmunoestimuladoras que se unen específicamente a bcma
WO2024246083A1 (en) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Bispecific antibodies targeting bcma and cd28
CN121285742A (zh) 2023-06-08 2026-01-06 基因泰克公司 用于淋巴瘤的诊断和治疗方法的巨噬细胞特征
AU2024311339A1 (en) 2023-06-21 2026-01-08 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists
WO2024263845A1 (en) 2023-06-22 2024-12-26 Genentech, Inc. Treatment of multiple myeloma
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
AU2024300009A1 (en) 2023-07-21 2026-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies that broadly target coronaviruses
WO2025021790A2 (en) 2023-07-24 2025-01-30 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
AU2024322991A1 (en) 2023-08-09 2026-01-08 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025038492A1 (en) 2023-08-11 2025-02-20 Abalytics Oncology, Inc. Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
WO2025045250A1 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Anti-human factor d antibody constructs and uses thereof
WO2025064539A1 (en) 2023-09-19 2025-03-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Herv-e antibodies and methods of their use
EP4537907A1 (en) 2023-10-10 2025-04-16 Enthera S.r.l. Cd248 inhibitors and uses thereof
WO2025085489A1 (en) 2023-10-17 2025-04-24 Bristol-Myers Squibb Company Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
TW202517674A (zh) 2023-10-19 2025-05-01 德商拜耳廠股份有限公司 抗gpc3抗體及其放射性結合物
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025106427A1 (en) 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025111402A1 (en) 2023-11-21 2025-05-30 Board Of Regents Of The University Of Nebraska Anti-amyloid beta antibodies and related compositions and methods thereof
WO2025117384A1 (en) 2023-12-01 2025-06-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing influenza hemagglutinin stem-directed antibodies
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
WO2025137284A2 (en) 2023-12-21 2025-06-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants
WO2025174974A1 (en) 2024-02-14 2025-08-21 Bristol-Myers Squibb Company Anti-cd33 antibodies and uses thereof
WO2025179281A1 (en) 2024-02-23 2025-08-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of cardiovascular disease with antxr1 antibodies
WO2025184416A1 (en) 2024-02-27 2025-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single-domain antibodies and bispecific antibodies against hiv-1 and their use
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
WO2025199352A2 (en) 2024-03-20 2025-09-25 Juno Therapeutics, Inc. Antibodies specific for solute carrier family 34 member 2 (slc34a2)
US20250295801A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody drug conjugates, and uses thereof
WO2025215124A2 (en) 2024-04-12 2025-10-16 F. Hoffmann-La Roche Ag Combination treatment of glofitamab and chemotherapy
WO2025218725A1 (zh) * 2024-04-18 2025-10-23 徕特康(苏州)生物制药有限公司 靶向cd20和cd89的髓细胞衔接子抗体及其用途
WO2025226808A1 (en) 2024-04-24 2025-10-30 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2025238187A1 (en) 2024-05-15 2025-11-20 Cis Biopharma Ag Immunoconjugates targeting l1-cam
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
WO2025242909A1 (en) 2024-05-24 2025-11-27 Paul Scherrer Institut CD30-targeting antibody-radioligand conjugates and their therapeutic use
WO2025250969A1 (en) 2024-05-31 2025-12-04 Vertex Pharmaceuticals Incorporated Anti-cd74 antibodies, conjugates and uses thereof
WO2025262564A1 (en) 2024-06-17 2025-12-26 Pfizer Inc. Use of anti-cxcr5 antibodies
WO2026003224A2 (en) 2024-06-26 2026-01-02 Iomx Therapeutics Ag Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097A (en) 1850-02-19 Elevating- and lowering carriage-tops
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989009402A1 (fr) 1988-03-30 1989-10-05 Toray Industries, Inc. PREPARATION LYOPHILISEE CONTENANT UN ANTICORPS DE L'INTERFERON beta ANTIHUMAIN MARQUE PAR UNE ENZYME ET KIT D'ANALYSE ENZYMATIQUE CONTENANT CETTE PREPARATION
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992007466A1 (en) 1990-11-05 1992-05-14 Bristol-Myers Squibb Company Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20030180290A1 (en) 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
JP2000516594A (ja) 1996-07-26 2000-12-12 スミスクライン・ビーチャム・コーポレイション 免疫細胞介在全身性疾患の改良された治療法
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
ES2335365T3 (es) 1996-11-27 2010-03-25 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteina a.
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP3919235B2 (ja) 1997-06-13 2007-05-23 ジェネンテク，インコーポレイテッド 抗体製剤
US20040191256A1 (en) 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
SK14812000A3 (sk) 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ES2261589T3 (es) 1998-05-06 2006-11-16 Genentech, Inc. Composicion de anticuerpos anti-her2.
JP2002522511A (ja) 1998-08-11 2002-07-23 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法
WO2000010007A2 (en) 1998-08-17 2000-02-24 California Institute Of Technology Devices and methods for analysis of non-ionic solutes
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
DE69941903D1 (de) 1998-11-09 2010-02-25 Biogen Idec Inc Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern
BR9915164A (pt) 1998-11-09 2003-01-07 Idec Pharma Corp Tratamento de malignidades hematológicas associadas com células de tumor circulantes usando anticorpo anti-cd20 quimérico
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
ES2254174T3 (es) 1999-05-07 2006-06-16 Genentech, Inc. Tratamiento de enfermedades autoinmunes con antagonistas que se unen a marcadores de superficie de linfocitos b.
EP1194167B1 (en) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
BR0013201A (pt) 1999-07-12 2002-04-30 Genentech Inc Método de bloqueio de uma resposta imunológica a um antigeno externo em mamìferos através da utilização de um antagonista que se liga ao cd20, método de tratamento de mamìferos, método de tratamento de uma doença de enxerto contra hospedeiro ou hospedeiro contra enxerto em mamìferos, método de insensibilização de mamìferos que aguardam transplante e artigo industrializado
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
AU784971B2 (en) 1999-08-11 2006-08-10 Biogen Inc. Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies
CN1169952C (zh) 1999-10-10 2004-10-06 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd20单克隆抗体的重链和轻链可变区基因及其应用
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
RU2305561C2 (ru) 1999-11-08 2007-09-10 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием антител против cd40l в комбинации с антителами против cd20 и/или химиотерапией и лучевой терапией
WO2001071005A2 (en) 2000-03-24 2001-09-27 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
CN1981868A (zh) 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
CA2405632A1 (en) 2000-04-25 2001-11-01 Idec Pharmaceutical Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
EP1299128A2 (en) 2000-06-20 2003-04-09 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
MXPA03000306A (es) 2000-07-12 2004-04-05 Idec Pharma Corp Tratamiento de malignidades de celulas b que usan una combinacion de anticuerpos supresores de celulas b y aplicaciones relacionadas con anticuerpos moduladores inmunes.
PT1305437E (pt) 2000-07-31 2010-11-12 Biolex Therapeutics Inc Expressão de polipéptidos biologicamente activos na lentilha de água
DE10043452A1 (de) 2000-09-04 2002-03-14 Basf Ag Formkörper mit einer tonmineralischen Beschichtung
US20020058029A1 (en) 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
US20020128448A1 (en) 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030103971A1 (en) 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
CA2436180C (en) 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
US20030211107A1 (en) 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020147312A1 (en) 2001-02-02 2002-10-10 O'keefe Theresa Hybrid antibodies and uses thereof
US20030077826A1 (en) 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
CA2442801A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with gntiii
EP1383532B1 (en) 2001-04-02 2011-05-04 Genentech, Inc. Combination therapy
WO2003061694A1 (en) 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression of the humoral immune response by anti-cd20 antibodies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
IL159422A0 (en) 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
MXPA04006357A (es) 2001-12-27 2005-03-31 Glycofi Inc Metodos para disenar estructuras de carbohidrato del tipo de mamifero.
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
JP4498746B2 (ja) 2002-02-14 2010-07-07 イミューノメディクス、インコーポレイテッド 抗ｃｄ２０抗体およびその融合タンパク質ならびに使用法
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20030180292A1 (en) 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
CA2819867A1 (en) 2002-03-19 2003-09-25 Stichting Dienst Landbouwkundig Onderzoek Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta (1,4)-n-acetylglucosaminyltransferase iii) expression in plants
ES2291626T3 (es) 2002-03-21 2008-03-01 Eli Lilly And Company Anticuerpos humanos de ligando anti-hfas antagonista y fragmentos asociados.
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
AU2003236019A1 (en) * 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
AU2003236017B2 (en) * 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
US20040132097A1 (en) 2002-06-19 2004-07-08 Bacus Sarah S. Method for predicting response to epidermal growth factor receptor-directed therapy
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
ES2347325T3 (es) 2002-09-12 2010-10-28 Greenovation Biotech Gmbh Metodo de produccion de proteinas.
MXPA05004022A (es) 2002-10-17 2005-10-05 Genmab As Anticuerpos monoclonales humanos contra cd20.
CA2508214A1 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US20060179501A1 (en) 2002-12-16 2006-08-10 Chan Andrew C Transgenic mice expressing human cd20
CA2549932C (en) 2002-12-20 2013-08-20 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
SG2013005590A (en) 2003-01-22 2015-06-29 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
JP2007528201A (ja) 2003-03-14 2007-10-11 ファルマシア・コーポレーション 癌治療のためのｉｇｆ−ｉ受容体に対する抗体
EP1613350B1 (en) 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
NZ543712A (en) 2003-06-05 2008-06-30 Genentech Inc Combination therapy for B cell disorders
BRPI0412217A (pt) 2003-07-29 2006-08-22 Genentech Inc método de avaliação da eficácia de anticorpo, métodos de imunoterapia, método de detecção de anticorpos neutralizantes a anticorpo terapêutico e método de avaliação da eficácia de antagonista
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
RU2006110036A (ru) 2003-08-29 2006-08-10 Дженентек, Инк. (Us) Лечение глазных расстройств анти-cd20
NO347530B1 (no) * 2003-11-05 2023-12-11 Roche Glycart Ag Et humanisert type II anti-CD20 antistoff og vertscelle som produserer et humanisert type II anti-CD20 antistoff samt en fremgangsmåte for fremstilling og en farmasøytisk sammensetning.
RU2006126099A (ru) 2003-12-19 2008-01-27 Дженентек, Инк. (Us) Детектирование cd20 при отторжении трансплантата
CA2549122A1 (en) 2003-12-19 2005-07-07 Genentech, Inc. Detection of cd20 in therapy of autoimmune diseases
KR20070001932A (ko) 2003-12-23 2007-01-04 리나트 뉴로사이언스 코퍼레이션 작용물질 항 티알케이씨 항체 및 그의 사용 방법
US20050288491A1 (en) 2004-02-17 2005-12-29 Wilson David S Super-humanized antibodies against respiratory syncytial virus
US20050276803A1 (en) 2004-04-16 2005-12-15 Genentech, Inc. Method for augmenting B cell depletion
CN1997893A (zh) 2004-04-16 2007-07-11 健泰科生物技术公司 抗体测定法
AR049021A1 (es) 2004-04-16 2006-06-21 Genentech Inc Tratamiento de trastornos con un anticuerpo que se une a cd20
JP2007536246A (ja) 2004-05-05 2007-12-13 ジェネンテック・インコーポレーテッド 自己免疫疾患の予防法
US7514223B2 (en) 2004-05-15 2009-04-07 Genentech, Inc. Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
CN106075435A (zh) 2004-06-04 2016-11-09 健泰科生物技术公司 用于治疗多发性硬化的方法
MXPA06014067A (es) 2004-06-04 2007-02-15 Genentech Inc Metodo para tratar lupus.
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
EP1781378A2 (en) 2004-07-22 2007-05-09 Genentech, Inc. Method of treating sjögren's syndrome
EP1778728A2 (en) 2004-08-19 2007-05-02 Genentech, Inc. Polypeptide variants with altered effector function
KR20070050950A (ko) 2004-09-08 2007-05-16 제넨테크, 인크. 사멸 수용체 리간드 및 ｃｄ20 항체의 사용 방법
JP2008512479A (ja) 2004-09-08 2008-04-24 ジェネンテック・インコーポレーテッド デスレセプターリガンド及びｃｄ２０抗体の使用方法
MX2007002883A (es) 2004-09-13 2007-06-15 Macrogenics Inc Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo.
ZA200702335B (en) 2004-10-05 2009-05-27 Genentech Inc Method for treating vasculitis
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
JP2008524241A (ja) 2004-12-17 2008-07-10 ジェネンテック・インコーポレーテッド 従来の治療の効果がなかった患者の自己免疫性疾患の血管新生阻害治療
CN101128586A (zh) 2004-12-22 2008-02-20 健泰科生物技术公司 制备可溶性多跨膜蛋白的方法
DOP2006000013A (es) 2005-01-13 2006-07-15 Genentech Inc Dosis de anticuerpos en el tratamiento de enfermedades asociadas a las celulas b
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AR053579A1 (es) 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
BRPI0612972A2 (pt) 2005-04-22 2010-12-14 Genentech Inc mÉtodo para tratar doenÇa de alzheimer, mÉtodo para tratar demÊncia, artigo de fabricaÇço e usos de um anticorpo cd20
RU2007142523A (ru) 2005-05-18 2009-06-27 БИОГЕН ИДЕК Инк. (US) Способы лечения фиброзных состояний
US7601335B2 (en) 2005-05-20 2009-10-13 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
KR20080032065A (ko) 2005-06-03 2008-04-14 제넨테크, 인크. 푸코실화 수준이 조절된 항체의 생성 방법
CN101291954B (zh) 2005-08-26 2013-03-27 罗氏格黎卡特股份公司 具有改变的细胞信号传导活性的修饰的抗原结合分子
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007064911A1 (en) 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
US7708944B1 (en) 2006-06-13 2010-05-04 Research Foundation Of State University Of New York Ultra-sensitive, portable capillary sensor
MX2009010620A (es) 2007-04-02 2009-11-25 Genentech Inc Marcadores biologicos predictivos de respuesta de artritis reumatoide a antagonistas de celula-b.
WO2008157282A1 (en) 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
ES2941738T3 (es) 2007-07-09 2023-05-25 Genentech Inc Prevención de la reducción de enlaces disulfuro durante la producción recombinante de polipéptidos
KR100898362B1 (ko) 2007-07-10 2009-05-18 주식회사 그리폰 다목적 신발
CA2697482C (en) 2007-09-05 2016-05-31 F. Hoffmann-La Roche Ag Combination therapy with type i and type ii anti-cd20 antibodies
GB0718684D0 (en) 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
US20090214561A1 (en) 2007-09-24 2009-08-27 David Robert Close Treatment method
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
US20090110688A1 (en) 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
EP3441402A1 (en) 2007-10-30 2019-02-13 Genentech, Inc. Antibody purification by cation exchange chromatography
BRPI0820604A2 (pt) 2007-12-21 2017-05-09 Genentech Inc método de purificação de um anticorpo cd20, cristal de um anticorpo cd20, composição e método destinado ao tratamento de uma condição ou doença associada ao cd20
US20090162351A1 (en) 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
CN101945667A (zh) 2007-12-21 2011-01-12 健泰科生物技术公司 利妥昔单抗不应性类风湿性关节炎患者的疗法
EP2234600B1 (en) 2007-12-21 2014-08-20 F. Hoffmann-La Roche AG Antibody formulation
CN101983071A (zh) 2008-03-25 2011-03-02 罗氏格黎卡特股份公司 具有增加的抗体依赖性细胞毒性(adcc)的ⅱ型抗cd20抗体与环磷酰胺、长春新碱和多柔比星联合治疗非霍奇金淋巴瘤的应用
US20090269339A1 (en) 2008-04-29 2009-10-29 Genentech, Inc. Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
US8021850B2 (en) 2008-07-14 2011-09-20 Ribo Guo Universal tandem solid-phases based immunoassay
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
JP2012509269A (ja) 2008-11-17 2012-04-19 ジェネンテック， インコーポレイテッド 生理的条件下での高分子の凝集を低減するための方法及び製剤
KR20110097772A (ko) 2008-11-17 2011-08-31 제넨테크, 인크. 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CA2769595A1 (en) 2009-08-14 2011-02-17 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
EP3211094A3 (en) 2009-09-03 2017-11-01 F. Hoffmann-La Roche AG Methods for treating, diagnosing, and monitoring rheumatoid arthritis
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011131749A1 (en) 2010-04-23 2011-10-27 Glaxo Group Limited New 14 and 15 membered macrolides for the treatment of neutrophil dominated inflammatory diseases
EP2600895A1 (en) 2010-08-03 2013-06-12 Hoffmann-La Roche AG Chronic lymphocytic leukemia (cll) biomarkers
AR082693A1 (es) 2010-08-17 2012-12-26 Roche Glycart Ag Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
CN103502472B (zh) 2011-02-28 2017-06-06 弗·哈夫曼-拉罗切有限公司 生物标记物和用于预测对b‑细胞拮抗剂的响应的方法
US8592156B2 (en) 2011-08-08 2013-11-26 Roche Molecular Systems, Inc. Predicting response to anti-CD20 therapy in DLBCL patients
EP2892470A4 (en) 2012-09-06 2016-07-06 Freedom Innovations Llc METHOD AND SYSTEM FOR A PROSTHESIS DEVICE WITH SEVERAL FUNCTION LEVELS ACTIVATED THROUGH SEVERAL CONTROL SYSTEMS
CN104768581A (zh) 2012-09-07 2015-07-08 吉宁特有限公司 II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗

Also Published As

Publication number Publication date
AU2004287643C1 (en) 2012-05-31
HUE026669T2 (en) 2016-06-28
JP2018027088A (ja) 2018-02-22
TR201903329T4 (tr) 2019-04-22
ES2550311T3 (es) 2015-11-06
CN102373214B (zh) 2014-07-09
HRP20170398T2 (hr) 2019-06-28
KR101364858B1 (ko) 2014-02-19
NO20220263A1 (no) 2006-08-03
PL1692182T3 (pl) 2010-09-30
JP6125770B2 (ja) 2017-05-10
NZ547589A (en) 2009-05-31
ES2341009T3 (es) 2010-06-14
NO20210499A1 (no) 2006-08-03
ATE463513T1 (de) 2010-04-15
PT2348051T (pt) 2019-02-04
US20090010921A1 (en) 2009-01-08
ME01775B (me) 2011-02-28
US20240301079A1 (en) 2024-09-12
EP2348051B1 (en) 2018-12-19
US20160075794A1 (en) 2016-03-17
PT2380910E (pt) 2015-11-26
CN102373215A (zh) 2012-03-14
US20160076009A1 (en) 2016-03-17
MXPA06004836A (es) 2006-07-06
IL175367A0 (en) 2006-09-05
ES2615507T3 (es) 2017-06-07
US20230212303A1 (en) 2023-07-06
US20050123546A1 (en) 2005-06-09
CA2544865A1 (en) 2005-05-19
ECSP21023271A (es) 2021-05-31
ME02332B (me) 2016-06-30
IL232954A (en) 2015-09-24
NO347800B1 (no) 2024-03-25
BE2016C008I2 (enExample) 2021-08-16
DE602004026470D1 (de) 2010-05-20
SI1692182T1 (sl) 2010-06-30
JP2010081940A (ja) 2010-04-15
RS57466B1 (sr) 2018-09-28
TNSN06126A1 (en) 2007-11-15
PL2380910T3 (pl) 2015-12-31
HRP20151418T1 (hr) 2016-01-29
CA2544865C (en) 2019-07-09
EP2380911B1 (en) 2018-05-09
HRP20100303T1 (hr) 2010-07-31
CY1121206T1 (el) 2020-05-29
EA201100128A1 (ru) 2011-06-30
SG10202008722QA (en) 2020-10-29
CR11848A (es) 2011-04-04
KR20060130579A (ko) 2006-12-19
EP2348051A2 (en) 2011-07-27
SG160348A1 (en) 2010-04-29
EP1692182A2 (en) 2006-08-23
DK2077282T3 (en) 2017-01-30
US9296820B2 (en) 2016-03-29
PT2380911T (pt) 2018-07-04
RS54450B1 (sr) 2016-06-30
EA036531B1 (ru) 2020-11-19
HK1100005A1 (en) 2007-08-31
HRP20190333T1 (hr) 2019-05-03
CY1118719T1 (el) 2017-07-12
DK1692182T3 (da) 2010-05-31
BR122020013239B1 (pt) 2022-05-10
PL2380911T3 (pl) 2018-10-31
NO2018020I1 (no) 2018-06-27
EA202091901A1 (ru) 2020-11-24
BRPI0416262B1 (pt) 2022-04-12
DK2380911T3 (en) 2018-08-06
US20210002382A1 (en) 2021-01-07
FR15C0076I1 (enExample) 2016-01-01
EA200600905A1 (ru) 2006-12-29
JP6235521B2 (ja) 2017-11-22
NO341893B1 (no) 2018-02-12
BRPI0416262A (pt) 2007-01-09
NO20220904A1 (no) 2006-08-03
EP2077282B1 (en) 2016-12-28
ECSP066603A (es) 2006-10-17
IL175367A (en) 2014-11-30
SI2077282T1 (sl) 2017-03-31
KR101220691B1 (ko) 2013-01-14
PL2348051T3 (pl) 2019-05-31
JP4653109B2 (ja) 2011-03-16
NZ588860A (en) 2012-03-30
LU92632I2 (fr) 2015-11-02
ES2708095T3 (es) 2019-04-08
IL207347A (en) 2015-08-31
AU2004287643B2 (en) 2011-11-17
TR201809892T4 (tr) 2018-07-23
HK1167681A1 (en) 2012-12-07
CN102373214A (zh) 2012-03-14
EA025962B1 (ru) 2017-02-28
WO2005044859A2 (en) 2005-05-19
NO20062289L (no) 2006-08-03
NO347530B1 (no) 2023-12-11
EP2380910A1 (en) 2011-10-26
ES2672640T3 (es) 2018-06-15
SI2348051T1 (sl) 2019-03-29
ME03330B (me) 2019-10-20
PT1692182E (pt) 2010-05-13
LT2380911T (lt) 2018-07-10
JP2015134814A (ja) 2015-07-27
HUE038955T2 (hu) 2018-12-28
KR101364902B1 (ko) 2014-02-21
LT2348051T (lt) 2019-02-25
IL207347A0 (en) 2010-12-30
NL300801I2 (nl) 2017-09-19
LTC2380910I2 (lt) 2018-01-25
HUS1600013I1 (hu) 2016-04-28
CN104829719A (zh) 2015-08-12
IL235172A0 (en) 2014-11-30
JP2012254083A (ja) 2012-12-27
CY2015001I2 (el) 2016-06-22
UA91823C2 (ru) 2010-09-10
EP1692182B1 (en) 2010-04-07
EA015009B1 (ru) 2011-04-29
HK1167682A1 (en) 2012-12-07
DK2380910T3 (en) 2015-10-19
IL232954A0 (en) 2014-07-31
CY2015001I1 (el) 2016-06-22
FR15C0076I2 (fr) 2016-03-11
EA201300481A1 (ru) 2014-01-30
HUE042914T2 (hu) 2019-07-29
HK1213574A1 (zh) 2016-07-08
CN1902231A (zh) 2007-01-24
KR20120104419A (ko) 2012-09-20
EP2077282A3 (en) 2009-08-05
NO346167B1 (no) 2022-04-04
CY2016004I2 (el) 2016-08-31
SG10201504094SA (en) 2015-06-29
PT2077282T (pt) 2017-02-14
SI2380911T1 (en) 2018-07-31
HRP20170398T1 (hr) 2017-05-19
RS51334B (sr) 2011-02-28
US8883980B2 (en) 2014-11-11
CY1110301T1 (el) 2015-01-14
AU2004287643A1 (en) 2005-05-19
EP2380910B1 (en) 2015-09-30
WO2005044859A3 (en) 2005-08-04
CN1902231B (zh) 2015-05-20
LT2077282T (lt) 2017-03-10
CY2016004I1 (el) 2016-08-31
NO20171989A1 (no) 2006-08-03
US20160075793A1 (en) 2016-03-17
CY1120252T1 (el) 2019-07-10
KR20110129990A (ko) 2011-12-02
NO346533B1 (no) 2022-09-26
EP2348051A3 (en) 2012-12-19
SI2380910T1 (sl) 2015-11-30
DK2348051T3 (en) 2019-03-18
RS55723B1 (sr) 2017-07-31
JP2008500017A (ja) 2008-01-10
RS58420B1 (sr) 2019-04-30
CN102373215B (zh) 2014-07-30
HUE031632T2 (en) 2017-07-28
EP2077282A2 (en) 2009-07-08
HRP20181204T1 (hr) 2018-09-21
EP2380911A1 (en) 2011-10-26
MX337587B (es) 2016-03-11
LU93001I2 (fr) 2016-05-17
PL2077282T3 (pl) 2017-08-31
ZA200604547B (en) 2007-07-25

Similar Documents

Publication Publication Date Title
MA31040B1 (fr) Anticorps anti-cd20 avec une augmentation de l'affinite de fixation sur le recepteur fc et de la fonction effectrice.
MA29279B1 (fr) Molecules de liaison d'antigenes se liant au recepteur egfr, vecteurs codant pour ces molecules et leurs applications
MA33536B1 (fr) Anticorps monoclonaux anti-cea humanisés obtenus par maturation d'affinité
Verkman et al. Biology of AQP4 and anti‐AQP4 antibody: Therapeutic implications for NMO
Shibuya et al. Fcα/μ receptor mediates endocytosis of IgM-coated microbes
MXPA06012601A (es) Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
TW200720439A (en) Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
WO2008105886A3 (en) HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP2275134A3 (fr) Utilisation d'anticorps optimisés en ADCC pour traiter les patients faibles répondeurs
WO2003106498A3 (en) Ox40 (=cd134) receptor agonistic and therapeutic use
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
MA29836B1 (fr) Proteines de fusion avec l'albumine
PL2004688T5 (pl) Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania
Könitzer et al. Reformatting rituximab into human IgG2 and IgG4 isotypes dramatically improves apoptosis induction in vitro
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
AU2256097A (en) A g protein-coupled receptor with an enlarged extracellular domain
JPWO2008084710A1 (ja) ヘルペスウィルス感染阻害剤、ヘルペスウィルスの感染阻害方法およびその利用
Liu et al. Epac1 Regulates Ephb1/Ephrin B1 in Retinal Müller Cells
MA33668B1 (fr) Anticorps chimériques spécifiques pour cd151 et leur utilisation dans le traitement du cancer
CR8389A (es) Anticuerpos cd20 con funcion del efector y afinidad de enlace al receptor fc mejoradas
Holtrop et al. Proteolysis increases the Fc-mediated binding of murine IgG2b to human EBV-transformed В cells, but decreases the expression of FCYRII and FceRII